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INTRODUCTION 
 
Interest in methicillin-resistant Staphylococcus aureus (MRSA), first discovered in 
1961(1), stems from a number of factors, including the magnitude of the infections, 
concern over the development of antibiotic resistance, and versatility of the organism to 
produce multiple toxins leading to variety of clinical syndromes. It has drawn greater 
attention since a variant, community associated MRSA (CA-MRSA)(2) was first 
described. The original description and subsequent studies have noted that CA-MRSA is 
distinguished from health-care associated MRSA (HA-MRSA) by a more limited 
antibiotic-resistance profile, differences in toxins produced, the susceptible populations, 
and a propensity for outbreaks.(3) Skin and soft-tissue infections (SSTIs) represent the 
majority of the community-associated MRSA(CA-MRSA) disease burden, making the 
dermatologist the first in line(4) to detect the changing epidemiology of CA-MRSA. 
Infections caused by community-associated MRSA (CA-MRSA) differ from usual 
healthcare-associated MRSA (HA-MRSA) in their epidemiological, clinical and 
microbiological characteristics(5), and most importantly in the drug susceptibility 
profiles.  
Since S.aureus is associated with significant morbidity(6) by causing primary and 
secondary pyodermas, the local epidemiological and microbiological understanding of 
this species is essential in appropriate health-care. Studies of MRSA have been carried 
out in different study populations, with incidence ranging from 1% to as high as 
74%.(7)(8)(9) Studies from India are infrequent, with contrasting prevalence of MRSA in 
different geographical locations and among diverse populations.(10)(11)(12)  
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CA-MRSA and MSSA also harbour specific virulence genes associated with skin and 
soft-tissue infections, particularly the Panton–Valentine leucocidin (PVL) genes(13) and, 
occasionally, exfoliative toxin genes. PVL has been associated with higher recurrence, 
virulence, transmission and severity of SSTIs(14)(15)(16) and mainly linked to primary 
skin infections like abscesses, severe necrotic skin infections and furunculosis The PVL 
locus is suggested as a stable genetic marker of these CA-MRSA strains(14), which 
explains the frequency of primary skin infections associated with PVL, while there are 
conflicting data suggesting PVL to be only of epidemiological significance(4) and not to 
affect the final outcome even in complicated SSTIs.(9) 
 
PVL-related infections further bear the risk of developing severe systemic infections such 
as bacterial endocarditis, necrotizing pneumonia and necrotizing fasciitis in both adults 
and children.(8)(17)  Guidelines and algorithms for the management of PVL associated 
MRSA have been suggested in the UK(18)(19) due to higher prevalence and variable 
susceptibility to antibiotics. (5)(20)  
The emergence of PVL positive isolates in community-associated staphylococcal 
pyodermas is globally described(21)(14), yet there were no reports of PVL associated 
pyodermas from the Indian subcontinent when this study was initiated. A descriptive 
prospective study on SSTIs would help in understanding the prevalence of CA-MRSA, 
guiding empiric therapy and also evaluate for the presence of PVL positive S.aureus in 
India. 
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Aims: 
 
1. To study the clinical and microbiological features of Staphylococcus aureus, 
isolated from outpatients presenting with pyodermas to the Dermatology 
outpatient department between July 2009 to July 2010. 
 
2. To compare the demographic and clinical features of methicillin-susceptible and  
methicillin-resistant S.aureus pyodermas 
 
3. To determine the presence of PVL (Panton-Valentine leucocidin) gene in 
S.aureus isolates and study associated demographic and clinical factors 
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REVIEW OF LITERATURE 
Staphylococcus (Greek: staphylē, "bunch of grapes" and kókkos, "granule") is a genus of 
Gram-positive bacteria. They are subclassified depending on their ability to produce 
coagulase. Staphylococcus aureus is coagulase-positive and catalase-positive, and is the 
most commonly isolated human bacterial pathogen.(22) It forms large, round, golden-
yellow colonies on blood agar, the etymological root of the species, aureus meaning 
"golden" in Latin. 
S.aureus is an important cause of skin and soft-tissue infections (SSTIs), endovascular 
infections, pneumonia, septic arthritis, endocarditis, osteomyelitis, foreign-body 
infections, and sepsis.(23) Methicillin-resistant S.aureus (MRSA) isolates are resistant to 
all available penicillins and other β-lactam antimicrobial drugs.(24) 
MRSA had been considered a nosocomial pathogen since its first description in the early 
1960s.(1) There have been increasing reports of community associated isolates of 
MRSA.(15) SSTIs represent the majority of the community associated MRSA(CA-
MRSA) disease burden, which means that dermatologists are first in line to pick up a 
changing epidemiology of MRSA.(5)(4) Infections caused by CA-MRSA differ from 
usual healthcare-associated MRSA (HA-MRSA) in their epidemiological, clinical, 
microbiological characteristics(5) and most importantly in the drug susceptibility profiles.  
 
Importance of Staphylococcus aureus in pyodermas:  
Cutaneous pyodermas constitute a major burden of preventable disease in dermatology 
outpatients.(16) A significant number of these pyodermas are caused by bacteriae, among 
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which S.aureus is one of the most commonly implicated organisms in developed 
countries(20) and in India.(25)  
 
Table 1.Prevalence of bacterial isolates from pyodermas(20)(25)  
 USA 
(n=26233) 
France 
{n=23012) 
Germany 
(n=17205) 
Italy 
(n=6884) 
Spain 
(n=11764) 
India  
(n=2783) 
S.aureus 23.7 29.2 18.8 24.2 17.0 38.1 
CoNS 11.1 13.5 11.8 12.6 13.1 5.5 
Enterococcus 24.9 10.3 16.0 19.7 18.1 2.2 
E.coli 8.8 9.9 14.5 7.8 12.7 17.4 
P. aeruginosa 8.7 8.9 5.3 16.1 8.4 11.8 
Klebsiella 5.0 2.8 4.4 2.5 3.9 6.7 
Enterobacter 3.9 3.7 2.8 3.2 3.9 2.8 
Proteus  2.9 4.6 3.6 3.8 4.6 2.3 
Citrobacter  1.7 0.9 1.6 1.3 3.9 2.9 
Serratia 1.5 1.3 0.7 0.7 2.3 NA 
Acinetobacter 1.5 1.0 1.1 0.2 1.1 10.2 
VGS 1.4 2.1 1.4 1.3 4.8 0.2 
Bacteroides 0.5 2.0 6.0 0.8 0.9 NA 
S.agalactiae 0.4 1.0 0.8 0.4 0.9 NA 
S.pyogenes 0.2 0.7 0.5 1.0 0.4 0.2 
Other species 3.8 8.2 10.7 4.6 6.8 0.7 
CoNS: Coagulase Negative Staphylococci; VGS: Viridans Group Streptococci 
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The normal skin is colonized by commensal bacteriae that live on the surface and within 
the follicles.(26) The organism, species, its abilities for virulence, number of organisms 
in the inoculum and even strain differences in the same species may be important in 
being pathogenic or non-pathogenic resident commensal flora.(27) 
The coagulase-positive Staphylococcus aureus, should not be considered as a resident on 
healthy skin in most subjects, although it frequents the anterior nares and perineal skin in 
one-third of the population. The other sites of carriage are the axillary skin, toe clefts and 
hands.(26) 
 
EMERGENCE OF MRSA AND LEUCOCIDIN: 
In 1961, soon after the introduction of methicillin, the first β-lactamase-resistant 
penicillin, strains of S.aureus that were resistant to methicillin were identified in the 
United Kingdom.(1) Prior to the mid-1990s, investigation into the epidemiology of 
MRSA was limited largely to the health care setting because it was rare that MRSA 
strains would infect otherwise healthy people.(28) The recognized risk factors then 
identified for MRSA infection and colonization included recent hospitalization; other 
exposures to the health care system; residence in a long-term care facility(29), acute-
rehabilitation unit(30); the presence of an indwelling line or catheter; surgical wounds; 
chronic liver, lung, or vascular disease; malignancy; recent exposure to antibiotics; 
intravenous drug use(29); and exposure to a patient with any of these risk factors for 
MRSA.(31) From the early 1990s onward, MRSA infections were reported in otherwise 
healthy young individuals, and the respective strains named “community-associated 
MRSA”(CA-MRSA).(32)(33) CA-MRSA is distinct from HA-MRSA.(34) HA-MRSA 
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corresponds to definite predominant clonal lineages of the S.aureus population with some 
of them having pandemic dissemination (35), whereas CA-MRSA strains usually 
represent different lineages. Owing to the confusion concerning clear definitions of 
MRSA detected outside the hospital setting, there are several limitations of the current 
data on CA-MRSA.(36) 
Although the pathogenicity and virulence of S.aureus is related to various surface 
proteins, epidemiological data revealed that synergohymenotropic toxins, also called 
leucocidin, described by Panton et al, is preferentially linked to furuncles, cutaneous 
abscesses and severe necrotic infections.(7)(37)(38) 
Lina et al(8) demonstrated 93% Panton Valentine leucocidin(PVL) positive isolates in 
community acquired S.aureus in furuncles and 85% in severe necrotic hemorrhagic 
pneumonia, from clinical samples collected between 1985 till 1998 in Lyon, France. 
While there were multiple prospective studies in Europe in France, UK and Germany, the 
first clinical isolate known to carry the PVL genes from Asia was reported in 2003.(39) In 
India, reports of MRSA have been present since 1980s although the major studies 
appeared in early 1990’s, including surveillance studies and multicentric analysis in 
1996.(40)(41) The first report of PVL however was only in 2009.(17) PVL harboring 
S.aureus have been suggested in large numbers in India from a multicentric trial on 
retapamulin.(21) 
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Emergence of MRSA in dermatology outpatients 
Since the most frequent of infections caused by S.aureus are SSTI’s, it is only obvious 
that cutaneous infections by staphylococcus would indicate the first changes in 
epidemiology and the resistance patterns. Until 1987 no MRSA was isolated in a 
dermatology outpatient clinic(42), whereas a gradual increase in infections with MRSA 
from 1.5% of all S.aureus in 1988 to 11.9% in 1996 in the same dermatology outpatient 
facilities was observed, and the prevalence is still increasing.(43) McBride et al.(42) 
studied 116 isolates from 2 different dermatology outpatients in Houston, Texas, USA 
and found none of the isolates to be methicillin-resistant. Uchizono et al.(44) reported 
MRSA strains in Japan in 1990 from various departments at the Kagoshima University 
Hospital, including the dermatology outpatient department.  
 
In a randomised, double-blinded, placebo-controlled trial with cephalexin for 
uncomplicated cutaneous pyodermas in 2007 (45), S.aureus was isolated from 70.4% of 
abscess cultures. Of the isolates tested, 87.8% were MRSA, 93% of which were positive 
for PVL genes. This study demonstrated the extremely high prevalence of CA-MRSA 
associated with PVL. 
There are totally seven published Indian studies that have looked into cutaneous 
pyodermas as of date.(11)(12)(46) There was a report of 10 cases of MRSA isolation in a 
dermatology inpatient setting in Mumbai in 2003.(46) These patients were inpatients who 
were found to have MRSA on wet lesions, which were swabbed, indicating possible 
primary or secondary infection or colonization. Retrospective analysis of pus swabs 
collected from hospitalized patients in New Delhi in 2004 showed a high prevalence of 
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38.6% of MRSA.(25) This prevalence of MRSA was noted to be higher than elsewhere in 
India, from earlier studies from Nagpur(47) and Vellore.(40) All these studies are done 
on clinical specimens from in-patients. These isolates might include HA-MRSA and 
hence may not be representative of the community prevalence of MRSA associated with 
SSTIs. 
MRSA is reported from general population cohorts in dermatology outpatient 
departments from Mangalore(11) and Mumbai.(12) However, both studies showed 
variable prevalences of 11% and 0.9% respectively of MRSA in pyodermas from Indian 
patients. In a pediatric cohort in New Delhi, Sardana et al. (48) noted 6.9% prevalence of 
MRSA. Thind et al. (49) recently reported a prevalence of 9.6% of MRSA in a 
dermatology outpatient from a tertiary care hospital in New Delhi in 2010. While these 
studies showed a relatively low prevalence of MRSA in the Indian setting, conflicting 
data is presented in a study from the general population elsewhere in North India from 
Chandigarh with MRSA prevalence being 23.08%.(50)  
In another retrospective analysis, Shenoy et al(51) described 83 CA-MRSA strains 
isolated from SSTIs from Mangalore. This retrospective study carried out by the 
microbiology department did not provide data on the prevalence on MRSA and discussed 
the antimicrobial susceptibility profiles of CA-MRSA in isolates from SSTIs, suggesting 
a variable antimicrobial susceptibility in CA-MRSA as compared to HA-MRSA. Thind et 
al(49) also showed that CA-MRSA are more likely to be non-multi resistant oxacillin 
resistant Staphylococcus aureus (NORSA), allowing more therapeutic options for 
treatment. 
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The prevalence of MRSA in Indian patients, especially in different geographic centres, 
urban or rural, are probable to vary, but there is dearth of data as to guide empiric therapy 
or help establish guidelines for management. In the event of MRSA prevalence being 
greater than 10%, a culture may be necessary, if clinically indicated, for appropriate 
therapy.(19) 
Community associated MRSA 
The terms CA-MRSA and HA-MRSA have been used to call attention both to the 
genotypic differences of certain MRSA isolates as well as to the epidemiological and 
clinical features of the pyodermas that they cause. Jappe et al.(4) has tried to delineate 
these differences in his study on cutaneous pyodermas, in similar lines as Del Guidice et 
al.(5) An essential component of epidemiological studies has been to define the clinical 
burden of CA-MRSA and HA-MRSA isolates, both of which circulate in the community. 
Important concepts bearing on these definitions are (i) the setting in which the MRSA 
infection begins; (ii) current or prior patient exposure to health care settings; (iii) poorly 
defined CA-MRSA patient risk factors, including prior MRSA infection; (iv) genetic 
characteristics and antibiotic susceptibilities of the causative MRSA isolate; and (v) the 
clinical syndrome manifested by the patient. (4)(15)  
Case definition of CA MRSA 
In 2000, the CDC created a case definition for a CA-MRSA infection: any MRSA 
infection diagnosed for an outpatient or within 48 hours of hospitalization if the patient 
lacks the following health care-associated MRSA risk factors: hemodialysis, surgery, 
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residence in a long-term care facility or hospitalization during the previous year, the 
presence of an indwelling catheter or a percutaneous device at the time of culture, or 
previous isolation of MRSA from the patient.(52) All other MRSA infections were 
considered to be HA-MRSA. This case definition was initially used to demonstrate that 
MRSA infections were occurring among healthy people in the community without health 
care exposure.(53)  
Table 2. Differences between HA-MRSA and CA-MRSA (19) 
Parameter HA-MRSA CA-MRSA 
 
Typical patient elderly, debilitated and/or 
critically or chronically ill 
young, healthy people; students, 
professional athletes and military 
service personnel 
Infection site often bacteraemia with no obvious 
infection focus. Also surgical 
wounds, open ulcers, IV lines and 
catheter urines. May cause 
ventilator associated pneumonia 
predilection for skin and soft 
tissue, producing cellulitis and 
abscesses. May cause necrotising 
community acquired pneumonia, 
septic shock or bone and joint 
infections 
Transmission within healthcare settings; little 
spread among household contacts 
community-acquired. May spread 
in families and sports teams 
Clinical setting 
of diagnosis 
in an inpatient setting, but 
increasingly HA-MRSA 
infections in soft tissue and urine 
are occurring in primary care 
in an outpatient or community 
setting 
Medical 
history 
history of MRSA colonization, 
infection, recent surgery; 
admission to a hospital or nursing 
home, antibiotic use; dialysis, 
permanent indwelling catheter 
no significant medical history or 
healthcare contact 
Virulence of 
infecting strain 
Community spread is limited, 
PVL genes usually absent 
community spread occurs easily. 
PVL genes often present, 
predisposing to necrotising soft 
tissue or lung infection 
Antibiotic 
susceptibility 
often multiresistant with result 
that choice of agents often very 
limited 
generally susceptible to more 
antibiotics than HA-MRSA 
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PVL and CA-MRSA infections 
PVL is a two-component S.aureus pore-forming protein encoded by the lukF-PV and 
lukS-PV genes. It was first described in 1894 by Van de Velde and was associated with 
SSTIs in 1932 by Panton.(13) The genes encoding PVL, which can spread from strain to 
strain by bacteriophages, were previously believed to be present in fewer than 5% of 
unselected clinical S.aureus isolates before the advent of CA-MRSA strains in the mid-
1990s, although the genes were transiently found in a circulating ST30 clone in Japan in 
1979 to 1985.(54) 
PVL is a bi-component (lukS-PV and lukF-PV) pore forming exotoxin that targets cells 
of the immune system such as polymorphonuclear cells.(55) PVL has been associated 
with higher recurrence, virulence, transmission and severity of SSTIs (skin and soft tissue 
infection) and mainly linked to primary skin infections like abscesses, severe necrotic 
skin infections and furunculosis.(4) The prevalence of PVL in S.aureus can be as high as 
55-93% isolates from primary cutaneous infections. (4)(5)(8)(56)(57) PVL-related 
infections further bear the risk of developing severe systemic infections such as bacterial 
endocarditis, necrotizing pneumonia and necrotizing fasciitis in both adults and 
children.(8)(22) (58) 
An intercontinental study with isolates from North America, Europe and Australasia 
showed CA-MRSA strains to share a type IV SCCmec cassette and the PVL locus, 
whereas the distribution of the other toxin genes was quite specific to the strains from 
each continent.(14) The PVL locus represents a stable genetic marker of these CA-
MRSA strains. 
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Guidelines and algorithms for the management of PVL associated MRSA have been 
suggested in the UK(19), while there are no prospective studies targeted at PVL 
associated staphylococcal SSTIs from India till date. 
In the United States, carriage of the PVL genes has been closely linked to infections 
caused by CA-MRSA strains in numerous epidemiological studies. In 2000, a large study 
from Minnesota found that 77% of patients with infections caused by CA-MRSA isolates 
(by the CDC case definition) were PVL+, but only 4% of HA-MRSA isolates were PVL+ 
.(3) Among 812 military recruits in Texas in 2003, 66% of 45 MRSA strains colonizing 
the nares of recruits or causing infections among them were PVL+.(59) Among MRSA 
isolates from detainees in the San Francisco County Jail, more than 70% were PVL+; of 
MRSA isolates from a clinic specializing in the treatment of SSTIs (all collected in 2000), 
69% were PVL+. All PVL+ MRSA strains also carried the SCCmec type IV element.(60)  
While PVL has been strongly linked epidemiologically to prevalent CA-MRSA strains, it 
is not known with certainty how they contribute to their fitness and/or virulence or if they 
are merely a marker for other fitness or virulence determinants. PVL+ strains carrying 
SCCmec type IV, V, or VT with varied background genotypes in many geographic 
settings have now been identified, although the chromosomal site of PVL gene 
integration lacks any known genetic linkage to the insertion site of SCCmec elements. 
Moreover, no other S.aureus toxin genes have been associated as strongly with CA-
MRSA strains as PVL.(14) PVL genes are rarely found in MRSA strains carrying 
SCCmec types I, II, and III. There are reports of PVL associated with VT    strains from 
Taiwan in children with SSTI and atopic dermatitis.(61) 
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In the United States, PVL genes have been almost universally detected among CA-MRSA 
strains causing SSTIs.(62) In Queensland, Australia, in 2004 to 2005, 59% of SSTIs 
caused by PVL+ S.aureus strains were designated "furunculosis," compared with only 
10% of SSTIs caused by PVL-negative strains.(63) 
The first prospective study on the emergence of MRSA in dermatology patients was 
conducted in France(5), where they found 11% MRSA in strains collected between 1999-
2003. Of these 11%(22 isolates), CA-MRSA accounted for 27% of  these, 100% being 
positive for PVL. Del Guidice noted a greater severity of the clinical cases 
(abscesses/furuncles) associated with CA-MRSA necessitating surgical incision and 
drainage in most cases. This was in contrast to 77% positive CA-MRSA isolates 
described by Naimi et al(3) in 2003 although the clinical severity of skin infections were 
not described. Sardana et al(48) reported a low prevalence (6.7%) of MRSA in a pediatric 
cohort from North India, in response to this study, suggesting that probably the age 
cohort and the geographical locations were important. 
In the largest prospective study so far done on cutaneous pyodermas directed at PVL+ 
isolates at the University of Heidelberg, Germany, Jappe et al(4) noted 20/36 patients 
with deep skin infections having PVL-positive strains (55% of furuncles and 56% of 
abscesses). Similarly designed studies had revealed results on PVL-positive strains from 
deep skin infections with rates between 35.2 and 70.8%.(56)(57) The study also indicated 
that not everyone with invasive S.aureus infections carries PVL-positive (methicillin-
resistant) strains, which contradicts the significance of PVL positivity as a conditio sine 
qua non (7)(8) for the development of deep skin infection.  
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Figure 1. Schematic diagram of key proteins associated with resistance and virulence in CA-MRSA 
(Adapted from David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: 
epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 2010 
Jul;23(3):616-687.) 
 
In Asia, the reported occurrence of MRSA infections that have onset in the community 
and the rate of PVL gene carriage have varied by country. In Taiwan, PVL+ CA-MRSA 
strains of a single background type commonly cause infections. PVL genes were 
identified in all 17 isolates in one study of CA-MRSA infections in children, the majority 
of whom had SSTIs.(64)  
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In South Korea and China, PVL+ strains remain rare among reported community-onset 
MRSA infections. Only 1 of 138 MRSA isolates from patients in South Korea with CA-
MRSA infections (by CDC criteria) in 2004 to 2005 was PVL+.(65)  
The first published report of PVL positive strain from India was described in a MRSA 
isolate from Chennai, where a 13 year old boy had developed invasive septicemia and 
respiratory distress requiring acute medical care, the initial symptoms being a boil with 
fever.(17) 
Emergence of PVL positive isolates in CAMRSA and HAMRSA has been reported from 
Chennai, India in 2009.(66) PVL positive strains have also been described from nasal 
swabs of epidemic MRSA in patients with SSTIs in Bangalore, India(67) in 2010 and 
from random isolates in MSSA and MRSA isolates from miscellaneous collections in 
Mumbai.(68) 
In a study on molecular epidemiology of MRSA and MSSA isolates from global clinical 
trials(21), isolates were recovered from patients with uncomplicated skin infections in 10 
different countries during five phase III global clinical trials of retapamulin, a new topical 
antibiotic agent. This study revealed a potentially disturbing finding that there were large 
numbers of PVL-positive MSSA isolates collected in South Africa and India. While the 
frequency of PVL-positive MSSA is generally considered to be low around the world, 
this study, in agreement with other recent work by Bae et al(9), provides evidence that 
some regions may have exceptional high levels of PVL-positive isolates. The data from 
India remains grossly underrated probably because there have been hardly any studies 
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directed towards the same. Bae et al(9) demonstrated that in complicated SSTIs, the 
presence of PVL did not alter the outcome of disease. 
Role of PVL in the pathogenesis of MRSA infections: the “spider-bite” 
PVL is a leukocidin that can lyse the cell membrane of human neutrophils, although its 
importance in pathogenesis is controversial. Recent evidence suggests that PVL may also 
inactivate mitochondria (69) and culminate in apoptosis. In animal models, PVL has been 
shown to be dermonecrotic(70), perhaps explaining the pathobiology of the characteristic 
skin lesions associated with CA-MRSA SSTIs. The lesions often resemble an injury 
produced by a spider bite(71), although common house spiders were not found to be 
carriers of CA-MRSA.(72) 
Known risk factors for CA-MRSA (22): 
Neonates  
Children beyond the neonatal period  
Athletes  
Household contacts of MRSA SSTI 
patients  
Emergency department patients  
Urban underserved communities 
 
Detainees in jail or prison  
Cystic fibrosis patients  
Military personnel  
Men who have sex with men HIV patients  
Veterinarians, livestock handlers, and pet 
owners 
Indigenous populations  
 
Neonatal MRSA Infections 
Several neonatal MRSA outbreaks have been linked to CA-MRSA strains have been 
associated with visiting fathers, maternal mastitis, expressed breast milk, peripartum 
maternal MRSA infection, and health care workers colonized or infected with MRSA, 
implying a community source.(73) 
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Vertical transmission undoubtedly plays a role. There is evidence that vaginal 
colonization with S.aureus is common (74), but vaginal MRSA colonization is unusual 
and has rarely been linked to neonatal infection. In New York City in 2005, 0.47% of 
2,963 pregnant women undergoing culture for group B streptococcal vaginal colonization 
had vaginal MRSA colonization.(75) 
Colonization in the hospital by means other than vertical transmission likely plays a 
major role in neonatal colonization. Colonization of mothers was associated with black 
race, antibiotic use during pregnancy or intrapartum, and attendance by another child of 
the mother at a day care or an after-school program.(76)  
In Japan, oropharyngeal MRSA colonization in the first week of life in extremely low-
birth weight infants in an intensive care unit in 1997 to 2003 was associated with an 
increased risk of MRSA sepsis and with MRSA colonization during week 6 of life. Those 
authors hypothesized that colonization of the oropharynx in the first week of life with 
other, nonpathogenic bacteria may protect against colonization with MRSA.(77) 
Children beyond neonatal period 
Children who presented in 2002 to 2003 to Johns Hopkins University Hospital with a skin 
infection caused by S.aureus were more likely to have an MRSA infection if they were 
African American or if they lived near the hospital, an area with a high rate of 
poverty.(75) Of S.aureus SSTIs in children at the Johns Hopkins ED in 2003 to 2005, 
73% (217/296) were caused by MRSA; 81% were CA-MRSA infections (by the CDC 
criteria) in 2003, and this percentage increased to 85% in the second year.(78)  
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In Asia, reports that identified isolates from children were predominantly ST59 and PVL+ 
and carried SCCmec type V or VT have come from Taiwan, South Korea, and Japan.(61) 
In Buenos Aires, Argentina, in 2005, five SSTIs in children without exposure to the 
health care system were caused by PVL+ MRSA strains carrying SCCmec type IV.(79) At 
a clinic in Athens, Greece, 88 CA-MRSA infections (by CDC criteria) among children 
younger than 14 years old were recorded in 2003 to 2005; 68% (28/41) of the strains 
belonged to one PFGE clonotype (similar to the PFGE type of ST80 strains) that was 
PVL+ and SCCmec type IV. Twenty of the 28 strains (71%) belonging to this clonotype 
were isolated from patients with SSTIs.(80) The study from University of Heidelberg, 
Germany showed a higher risk of CA-MRSA and PVL carriage in younger 
individuals.(4) 
In Narketpally, Andra Pradesh, India, in 2006, 12/392 (3.1%) children aged 5 to 15 years 
had nasal carriage of MRSA, but genotyping studies were not conducted.(81) In New 
Delhi, 3/89 (3.4%) of all isolates from pyodermas in children below 12 years of age were 
found to have MRSA.(48) 
Thus, CA-MRSA infections and carriage have been reported across the world including 
India; pediatric infections may be a harbinger of an epidemic to come in the general 
population.(82)  
Athletes 
While MRSA SSTIs have afflicted participants in many sports, football teams(American 
football) have been most frequently implicated. In a meta-analysis of players from three 
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division I college football teams in 2003 to 2006, MRSA infections occurred in 6.7% 
(33/491) players, primarily on the extremities, with no relationship to position played.(83) 
 
Household contacts of MRSA SSTIs 
In Europe, where contact tracing of index MRSA cases is commonly performed, several 
case reports demonstrated household transmission.(84) In Greece in 2003 to 2005, among 
88 CA-MRSA infections of children, 15.9% had suspected transmission of MRSA from 
family members.(80) 
Reports of household contact transmission of CA-MRSA have been documented among 
health care workers(85) and by heterosexual spread(86), besides fomites as a cause for 
spread in patients with SSTIs. 
 
Low socioeconomic status and overcrowding 
Although there is no direct evidence for the same, the high prevalence of CA-MRSA 
among emergency departments (EDs) in the USA may index towards the same. EDs 
serve as a safety net that provides health care for uninsured populations, and thus, the 
number of SSTIs treated may reflect the prevalence of these infections in communities 
with a low socioeconomic status (SES).(87)  
Cultured skin lesions among adults presenting to an ED in Cincinnati with an SSTI in 3 
months during 2005 yielded MRSA at a rate of 58%. Risk factors for MRSA infection 
included in a best-fit multivariable regression model were young age, sexual contact in 
the past month, the presence of an abscess cavity, and residence in a group home(88). 
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Incarcerated populations, like in prisons and jails have also been found to have high 
prevalence of MRSA, isolated from SSTIs. Poor hygiene, fomite spread, prior antibiotic 
use, trauma and self-draining of boils have been identified as risk factors in this distinct 
population.(89) 
Military personnel have a higher risk of transient colonization and SSTIs secondary to 
CAMRSA. Among active military service members deployed to Iraq in March to July 
2008, 66 were diagnosed with a carbuncle, furuncle, boil, or abscess, as determined by a 
retrospective review of administrative records, of which 68% culture-positive isolates 
were MRSA.(90) 
 
Medical comorbidities 
Higher risk of MRSA colonization is well described on the skin in atopic dermatitis, 
diabetes mellitus, chronic erosions, venous leg ulcers, hemodialysis and cystic fibrosis.(4)  
 
Men who have sex with men 
At a clinic in Boston where approximately 70% of patients were MSM by self-report, 
3.8% (30/795) of patients in 2005 to 2007 had MRSA recovered from the nares, the 
perianal region, or a skin infection. Among enrollees, 3.7% (29/795) had an SSTI at 
enrollment, and 9.2% (73/795) of patients had an SSTI during a 16-month period in 2005 
to 2007. The authors of that study suggested that skin-to-skin contact and multiple sexual 
partners may predispose one to SSTIs caused by MRSA.(91) 
Outside the United States, studies have not shown an elevated rate of MRSA carriage in 
MSM. 
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Clinical predictors of a pyoderma caused by MRSA 
Morphology. Purulent SSTIs caused by CA-MRSA strains are the most common clinical 
manifestations of CA-MRSA.  
An uncomplicated CA-MRSA SSTI typically presents as an abscess that may resemble a 
spider bite filled with purulent material.(22) This lesions present as spontaneously 
appearing raised tender red lesion, which may progress to develop a necrotic centre. This 
may lead to the suspicion of a ‘spider bite’ where such occurrences are common, e.g. 
North America or Australia. Most reports of such lesions have come from the USA and 
have not been as frequently reported from other countries. In the UK, where spider bites 
are rare, these ‘dermatonecrotic’ lesions increase the likelihood of a diagnosis of CA-
MRSA but are not pathognomic. They can also be found in infections due to PVL-
positive MSSA strains. 
Among adults with an abscess and surrounding erythema, the presence of a central black 
eschar had a positive predictive value of 94% and a negative predictive value of 45% for 
an MRSA isolate.(92)  
However, SSTIs can vary in appearance and can also present as folliculitis, paronychia, 
furuncle, felon, cellulitis with drainage (93) , or lymphadenitis.(94) Many other severe 
cutaneous complications of CA-MRSA have been reported and include extensive 
cellulitis, necrotizing fasciitis and purpura fulminans. Involvements of adjacent 
structures, either by direct spread or bacteraemia, such as septic thrombophlebitis, 
pyomyositis, septic arthritis and osteomyelitis, has all been described. 
The spectrum of disease caused by CA-MRSA appears to be similar to that caused by 
CA-MSSA. Furuncles, carbuncles and other abscesses appear to be the most frequently 
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reported clinical manifestations. Erythematous papules and nodules, folliculitis and/or 
impetigo are less common presentations of CA-MRSA.(19) 
No particular patterns of clinical presentation have yet emerged to allow differentiation 
from MSSA infections. Anecdotal reports suggest that recurrent (two or more in 6 
months) furuncles or abscesses, or clusters of infections within a household may indicate 
PVL-positive CA-MRSA. However, this pattern can also be seen in PVL-positive MSSA 
infections. Hence, except for the distinctive appearance noted above, MRSA SSTIs 
cannot be distinguished from SSTIs caused by other agents, including MSSA(95) on 
clinical grounds. 
 
Location. CA-MRSA abscesses can be found in diverse anatomical locations, including 
the breast(96), vulva(97), hand after clenched-fist injury(98), and neck.(94)  
 
Recurrence. Small studies have suggested that the recurrence of CA-MRSA SSTIs is 
common after treatment. A recurrence of 1 to 3 CA-MRSA (i.e., onset outside the health 
care setting) SSTIs at a distinct anatomical site occurred among 5 of 11 adult HIV-
infected patients in Chicago in 2003 to 2004; the intervals between index lesions and 
recurrences were not stated.(99) Among 87 MSM in New York City who presented with a 
CA-MRSA (i.e., onset in the community) SSTI, 31% had a recurrence within 6 months 
after the resolution of the initial infection. Recurrence rates among those receiving 
MRSA-appropriate and MRSA-inappropriate initial antibiotic therapy (21/63 versus 6/20) 
were similar.(100)  
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The likelihood of recurrence was not significantly different among HIV-infected patients, 
recipients of TMP-SMX prophylaxis, individuals with MRSA nasal colonization, or 
recipients of mupirocin for nasal decolonization.(101) 
 
Recurrence of skin infections and household clusters has been included in the risk-factor 
group for acquiring MRSA infection.(22), as is supported by studies both from 
developing (102) and developed countries.(16)(103) 
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MATERIALS AND METHODS 
 
Study design: Open, prospective study with cross-sectional study design 
Study setting: This study was conducted at the outpatient department of Department of 
Dermatology, Venereology and Leprosy in Christian Medical College and Hospital, 
Vellore. 
Study subjects:  
Eligibility: All patients presenting to the outpatient department with primary or 
secondary pyodermas were eligible for the study.  
Inclusion criteria: 
 All patients presenting to Dermatology OPD with pyoderma (primary or 
secondary) and willing to participate in the study 
Exclusion criteria: 
 Patient who has been partially or completely treated for the current 
episode of pyoderma with antibiotics with improvement of symptoms 
 Patient presenting with lesions classically known to be caused by non-
staphylococcal organisms 
 Patient presenting with staphylococcal pyodermas known to be caused by 
toxins such as Staphylococcal Scalded Skin Syndrome etc. 
 
Study period: July 2009 to July 2010 
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Research committee approval: The study was approved by the Institutional Review 
Board and Ethics Committee.  
 
Methodology:  
 
All patients with pyoderma who were eligible for the study after meeting the inclusion 
and exclusion criteria were asked to participate in the study.  
Case-definitions, definitions of demographic variables and definitions of clinical 
syndromes were used as given below: 
Primary pyoderma: Primary infections were those occurring on apparently normal skin. 
The diagnosis of primary infection was based on clinical findings as described. (27) 
Secondary pyodermas were those arising in damaged skin (traumatized skin, or a pre-
existing skin disease. (5) 
Recurrent pyoderma: 2 or more episodes of pyoderma, distinct from the index 
pyoderma, noted more than 6 days apart, over past 6 months. (99) 
Disseminated infection: 2 or more non-contiguous body sites with pyoderma (23) 
 
MRSA (methicillin-resistant S.aureus) (49): Strains of S.aureus that are resistant to the 
isoxazoyl penicillins such as methicillin, oxacillin and flucloxacillin. MRSA are cross-
resistant to all currently licensed β-lactam antibiotics. 
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CA-MRSA: 
Any MRSA infection diagnosed for an outpatient or within 48 hours of hospitalization if 
the patient lacks the following health care-associated MRSA risk factors: hemodialysis, 
surgery, residence in a long-term care facility or hospitalization during the previous year, 
the presence of an indwelling catheter or a percutaneous device at the time of culture, or 
previous isolation of MRSA from the patient. 
HA-MRSA: 
All the other MRSA isolated from inpatients after 48 hours of hospitalization or with any 
of the above mentioned risk-factors were considered to be HA-MRSA. 
Clinical syndrome definitions used in the study: (27) 
Impetigo: Impetigo is a contagious superficial pyogenic infection of skin; can be bullous 
or non-bullous. 
Ecthyma: Ecthyma is a pyogenic infection of the skin characterized by the formation of 
adherent crusts, beneath which ulceration occurs. 
Staphylococcal folliculitis: superficial folliculitis is an infection of the follicular ostium 
with S.aureus 
Furuncle: A furuncle is an acute, usually necrotic infection, infection of hair follicle with 
S.aureus. 
Carbuncle: deep infection of a group of contagious follicles with S.aureus, accompanied 
by intense inflammatory changes in the surrounding and underlying connective tissues, 
including the subcutaneous fat 
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Sycosis: subacute or chronic pyogenic infection involving the whole depth of the follicle 
 
 
Definition of Overcrowding used in this study (104):    
Room/person ratio wise: Accepted standards for living are one room for two persons, two 
rooms for three, three for five, four for seven, five or more for 10 persons, additional two 
for each extra room.  
Sex separation wise: Overcrowding is considered to exist if two persons over 9 years of 
age, not husband and wife of opposite sexes are obliged to sleep in the same room 
 
At the time of registration into the study, a written informed consent was taken from the 
patient (Annexure 1). All demographic and clinical variables were recorded in a 
standardized, pilot-tested proforma (Annexure 2). Historical data like recent travel was 
based on travel to foreign countries over the last 1 year. Data on history of prior 
antibiotics was noted based on prior available medical documentation or 1 year-recall. 
Data on previous type of pyoderma was taken depending on prior documentation in 
previous clinical records, which if not available, was noted as per the description offered 
by the patient. In the event of incomplete evidence on history or patient being unsure 
about the details regarding antibiotics, poor response to β-lactam antibiotics or prior 
pyoderma, the history was recorded as “not reliable”. Socio-economic status scoring was 
done using the modified Kuppuswamy scale, updated in 2007(105) . Data collection in 
the outpatient was done by the principal investigator alone, with expert advice from the 
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guide for clinical diagnosis. Size of the largest active lesion was measured only for 
primary pyodermas. Patient follow up was not a part of the study.  
 
Table 3: Socioeconomic scoring system: (104) 
 
Professsion Score Education Score Monthly 
income 
Score 
Profession 
or Honors 
7 Profession 7 >19575 12 
Graduate or 
post-
graduate 
6 Semi-
profession 
6 9788-19574 10 
Intermediate 
or post-high 
school 
diploma 
5 Clerical, 
shop owner 
or famer 
5 7323-9787 6 
High school 
certificate 
4 Skilled 
worker 
4 4894-7322 4 
Middle 
school 
certificate 
3 Semi-skilled 
worker 
3 2936-4893 3 
Primary 
school 
certificate 
2 Unskilled 
worker 
2 980-2935 2 
Illiterate 1 Unemployed 1 <980 1 
Socioeconomic status:  
26-29: Upper 
16-26: Upper middle 
11-15: Lower middle 
5-10: Upper lower 
<5: Lower 
 
In the event that the same patient presented twice during the study period, the data 
collected at the time of first presentation was considered for the study. The clinical 
isolates were not differentiated for colonisation or infection, and it was assumed that the 
isolated organisms were associated with the infection. 
Details of clinical examination were entered into the proforma, and pus collection was 
done under standard sterile methods with sterile cotton-tipped swabs. Pus was collected 
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following sterile aspiration or incision and drainage, wherever possible. The pus swabs 
were then transferred to the department of Clinical Microbiology, for diagnostic tests on 
the same day. 
 
Microbiological assessment to detect the causative organisms was done in the diagnostic 
laboratory with expert help, under the supervision of the co-investigator.  
 
Culture: 
Isolation and identification of Staphylococcus aureus, including determination of 
antibiotic susceptibility was carried out as per the SOP (Standard of protocol) currently 
followed in Department of Microbiology for the same. The procedure followed is as 
described below: 
On receipt, one swab was used to make a smear for Gram staining whereas the other was 
inoculated onto blood agar (BA), MacConkey agar (MA ) and thioglycollate medium 
(TG).  The BA was incubated at 370C in an atmosphere containing 5% CO2, while the 
MA and TG were incubated at 370C in an ordinary incubator. 
After overnight incubation, β-hemolytic colonies which showed gram positive cocci in 
clusters (GPC) were followed up and were identified to be S.aureus if they were tube 
coagulase  and mannitol positive.  
 
Susceptibility to oxacillin and erythromycin was determined by the Kirby-Bauer disc 
diffusion method as is being performed presently. An isolate was termed as MRSA 
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(methicillin resistant Staphylococcus aureus) if it was resistant to oxacillin and as MSSA 
(methicillin-susceptible  Staphylococcus aureus) if it was susceptible to oxacillin. 
 
S.aureus isolates were stored till the end of the study, and were revived later for PCR 
detection of Panton-Valentine leucocidin.  
 
PCR: 
Strains of MSSA and MRSA were subjected to PCR to detect the PVL gene following 
DNA extraction. 
DNA was extracted by boiling, 106 CFU/ml (CFU: colony forming units) of either MSSA 
or MRSA for 10 minutes. The supernatant was used as the template for amplification 
which was done using primers described by Lina et al(8). The primer sequences are as 
depicted below: 
 
luk-PV-1:  5'-ATC ATT AGG TAA AAT GTC TGG ACA TGA TCCA-3';  
luk-PV-2:  5'-GCA TCA AST GTA TTG GAT AGC AAA AGC-3' 
 
PCR Mix: The PCR reaction (50 µl) consisted of 25 µl of 2X PCR Master Mix 
(Fermentas Inc, Glen Burnie, MD, USA), 20 pmol of each primer (Sigma-Aldrich, 
Bangalore, India) and 5 µl of DNA template. 
Size of target: 433 bp 
Positive Control:  S.aureus ATCC 25923 
Negative control: S.aureus ATCC 43300 
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PCR amplification and detection:  The relevant target was amplified for 30 cycles  which 
included 30 s of denaturation at 940 C, 30 s of annealing at 550 C, and extension at 72 0 C 
for 1 minute).  The PCR products were resolved by electrophoresis through 1.5% agarose 
gels (Bangalore Genei, Bangalore, India) containing ethidium bromide.  The gel was 
analysed using a gel documentation system (GelDoc XR, Bio-Rad Laboratories, 
Hercules, CA, USA). 
 
Statistical analysis: 
Pilot data: We collected preliminary data by evaluating pus samples sent from 
Dermatology outpatient department as a pilot study over one month (randomly chosen as 
the month of November 2008). All the patients qualified for community associated 
infections as per the clinical definition of the 48 hour criterion and there were 76% of 
staphylococcal isolates of which 27% were MRSA.   
 
Sample size calculation: The sample size was calculated based on the primary objective 
which was to determine prevalence of MRSA in SSTIs. In the pilot study, the proportion 
of MRSA among all clinical isolates was 21%. Considering this information and a 
precision of +/- 5%, the sample size was calculated to be 266. We inflated the sample size 
by 10% to account for losses such as inadequate sample, etc. Hence, we planned to screen 
approximately 300 patients. 
 
Bias reduction: The assessor in the outpatient was not aware of the outcome, hence 
interviewer bias was minimised. Recall bias was minimized and adjusted for both MSSA 
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and MRSA groups by applying the same methodology of data collection for all patients. 
Clinical diagnosis was corroborated with a senior consultant. Outcome was based on 
standard methods of culture and sensitivity and standardized and controlled molecular 
tests like PCR. 
 
Data entry: Data was entered on Epi Info™ Version 3.5.1 software generated data-entry 
table. All outcome variables for this study were binary variables, denoting the presence or 
absence of the condition of interest. The baseline socio-demographic variables were 
either continuous or categorical. Clinical and laboratory information was recorded into a 
predetermined structured format at the time of data entry. 
 
Data analysis: With the help of STATA/IC Version 10.1 software package, frequency 
and percentages of all variables were tabulated. Preliminary analysis of demographic and 
other details was primarily descriptive. The prevalence of MRSA(with 95% confidence 
interval) was calculated. Comparison of socio-demographic and clinical risk factors 
between MRSA and MSSA groups was done using two-tailed t–test for continuous 
variables and chi-square test for categorical variables.. For each exposure of interest, 
prevalence ratio (with 95% confidence interval) was calculated.  
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RESULTS 
 
Patients presenting to Dermatology OPD with pyoderma 
 
  Inclusion/Exclusion criteria 
 
 
319 patients eligible 
Clinico-epidemiological data obtained  at this point 
 
 21 patients did not come for 
sample collection 
 
 
298 patients included in study 
Pus cultures sent to Microbiology Department 
 
Staphylococcus aureus     No growth/other bacteria 
 198        42/58 
 
 
Phenotypic characterization   Genotypic characterization for PVL (PCR) 
 
 
 
MSSA/MRSA    PVL positive/ PVL negative 
     144/54           29/59     
 
CA-MRSA  HA-MRSA 
    50/54      4/54 
 
Three hundred and nineteen patients met the inclusion criteria during the study period 
(July 2009 - August 2010) and consented to participate in the study. Of the eligible 
patients, 21/319 did not come for sample collection although they had consented to 
participate in the study. Pus culture was taken from 298/319 patients.  
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Table 3: Bacterial isolates from the pyodermas 
 
 
Bacteria isolated N=298 Percentage 
No growth 42 14 
S.aureus 198 66.4 
Beta-hemolytic streptococci 40 13.4 
Coagulase negative Staphylococcus 37 12.4 
Klebsiella  12 4.03 
Enterococcus 11 3.7 
Pseudomonas  9 3.0 
Proteus 6 2.0 
Morganella 3 1.0 
Non-fermenting gram negative bacteria 9 3.0 
E.coli 10 3.4 
Enterobacter 5 1.7 
Citrobacter  5 1.7 
Hemophilus  1 0.3 
Atypical mycobacteria 1 0.3 
 
 
 
Of all the samples sent, Staphylococcus aureus was isolated from 66.4% (198/298) and 
from 77.3% (198/256) of all culture positive pyodermas. Among all the S.aureus isolates, 
72.7% (144/198) were MSSA and 27.3% (54/198) were MRSA. Among all pyodermas, 
14% (42/298) did not show growth of any organism.  
 
 
Single organism isolate was seen in 207 (69.5%) samples, while 40 (13.4%) showed 
growth of two organisms, 7 (2.3%) showed growth of 3 organisms and 2 (0.7%) had 4 
organisms isolated. 
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Demographic profile of patients: 
 
Table 4: Demographic variables among patients   
 
Variable Number (N=298) Percentage 
Gender 
Male 
Female 
 
184 
114 
 
61.7 
38.3 
Age 
Pediatric 
Adult 
 
88 
210 
 
29.5 
70.5 
Geographic distribution 
Vellore district 
Rest of Tamilnadu 
Others 
 
168 
22 
108 
 
56.3 
7.3 
36.4 
Occupation 
Pre-school students 
 
46 
 
15.4 
School students 45 15.1 
College students 32 10.7 
Manual labourers 38 12.8 
Healthcare workers 27 9.1 
Housewives 48 16.1 
Self-employed business 19 6.4 
Others 43 14.4 
Facilities of residence 
Single 
Shared 
Overcrowding 
 
45 
165 
88 
 
15.2 
55.4 
29.4 
Socioeconomic status 
Upper 
Upper middle 
Lower middle 
Upper lower 
Lower 
 
40 
100 
99 
46 
13 
 
13.5 
33.6 
33.2 
15.3 
4.4 
Medical comorbidities 
Diabetes 
Hypertension 
Obesity 
Hypothyroidism 
Immunocompromised 
Immunosuppressed 
Malignancies 
 
24 
18 
6 
6 
1 
16 
8 
 
8.1 
6.0 
2.0 
2.0 
0.3 
5.4 
2.7 
 
Gender and Age: There were 184 males and 114 females included in the study of whom 
29.5% (88/298) were in the pediatric age group (≤ 16 years of age). The median age was 
30 years (0-86). (Interquartile range 8 to 46 years)  
 
 37 
 
Fig. 3: Age-wise distribution of patients 
 
Geographic distribution of patients: Majority (56.3 %) of patients were from Vellore 
district, 7.4% belonged to other parts of Tamilnadu and 36.3% were from elsewhere 
including 3 patients from Bangladesh, 1 each from Bhutan and  Belgium and the rest 
being from other parts of India.  
 
Occupation: Twenty seven (9.1%) patients were health-care workers. The rest of 
patients comprised of housewives (16.1%), manual labourers (12.8%), self-employed 
business (6.4%) and other professions.  
Facilities of Residence: Forty- five (15.2%) patients lived in single accommodation 
facility, 55.4% (165/298) in shared accommodation and 29.4% (88/298) in overcrowded 
places.  
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Socioeconomic status: Socioeconomic status distribution for the patients studied was as 
follows: 13.5% (40/298) in the upper status, 33.5% (100/298) in the upper middle and 
33.2% (99/298) in lower middle, 15.3% (46/298) in the upper lower and 4.4% (13/298) in 
the lower status. 
 
Comorbidities: 
 
Medical comorbidities: Medical comorbidities included diabetes 8.1% (24/298), 
hypertension 6% (18/298), obesity 2% (6/298), hypothyroidism 2% (6/298), 
immunocompromised 0.3% (1/298) immunosuppressed 5.4% (16/298) and malignancies 
2.7% (8/298). 
 
Dermatological comorbidities: Dermatological comorbidities included pemphigus (6), 
atopic dermatitis (5), psoriasis (4) and one each of Hyper IgE syndrome, Hansen’s 
disease, CHILD syndrome, Nekam’s disease and Netherton syndrome. 
 
Prior pyoderma in patients: A total of 45.3% (135/298) patients had history of prior 
pyodermas, with 25.2% (75/135) having recurrent disease within last 6 months and 
44.4% (60/135) with prior episodes occurring more than 6 months apart from the index 
episode. 114/135 patients had reliable history as per documentation in medical records 
(79/114) or recall (35/114). Of these 114 patients with prior episodes of pyoderma, the 
commonest type was furunculosis 58.8% (67/114) followed by impetigo 16.7% (19/114), 
superficial folliculitis 8.8% (10/114), and abscess 3.5% (4/114). 
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Prior antibiotic exposure among patients: Patients with exposure to both topical and 
systemic antibiotics were tabulated as per available medical records. At least single 
antimicrobial agent exposure (systemic or topical) was noted in 40.9% (122/298) and 
22% (66/298) of patients had history of exposure to at least two antimicrobial agents over 
the past 1 year. Exposure to β-lactam antibiotics was found in 27.5%, to macrolides  
9.06%, to quinolones 6.3%, to cotrimoxazole 3.02%, to linezolid 1.34% and to 
tetracyclines 1.01%. There was history of prior topical Neosporin® use in 6.04%, topical 
fusidic acid in 3.7% and topical mupirocin in 2.01%. 
 
History of poor response: A total of 8.1% (24/298) patients had history of poor response 
to β-lactam antibiotics. History of prior MRSA isolation was documented in 6/24 
patients. 
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Clinical Profile: 
 
Table 6: Clinical profile of patients 
Variable N=298 Percentage 
Type of pyoderma 
Primary 
Secondary 
 
234 
64 
 
78.5 
21.5 
Types of primary pyoderma(N=234) 
Furuncles 
Impetigo(non-bullous) 
Bullous impetigo 
Abscess 
Superficial folliculitis 
Carbuncles 
Others 
 
115 
33 
8 
32 
26 
3 
17 
 
49.1 
14.1 
3.4 
13.6 
11.1 
1.3 
7.3 
Types of secondary pyoderma(N=64) 
Eczema 
Ulcer 
Secondarily infected pemphigus 
Others 
 
24 
18 
9 
13 
 
37.5 
28.1 
14.1 
20.3 
Symptoms 
Asymptomatic 
Pain 
Itching 
Burning 
Others 
 
25 
268 
26 
4 
15 
 
8.4 
89.9 
8.7 
1.3 
5.1 
Signs 
Surrounding erythema 
Induration 
Lymphadenopathy 
Lymphangitis 
Necrotic changes 
Fever  
 
201 
36 
25 
20 
20 
8 
 
67.5 
12.1 
8.3 
6.7 
6.7 
2.8 
Site of involvement 
Head and neck 
Upper extremities 
Lower extremities 
Trunk 
Axillae 
Groins 
Palms/ soles 
Disseminated 
 
65 
26 
83 
60 
2 
1 
0 
61 
 
21.8 
8.7 
27.8 
20.4 
0.7 
0.3 
0 
20.7 
Size of largest active lesion (primary pyoderma,N=234) 
1-5 mm 
6-10 mm 
11-20 mm 
21-50 mm 
>50 mm 
 
 
 
27 
85 
67 
45 
10 
 
 
11.5 
36.3 
28.6 
19.2 
4.3 
Number of lesions(primary pyoderma, N=234) 
Solitary 
2-5 
6-10 
>10 
 
 
45 
116 
46 
27 
 
 
19.2 
49.6 
19.7 
11.5 
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The majority of patients in our study had primary pyodermas, accounting for 78.5% 
(234/298), with the rest being secondary pyodermas (21.5%). 
 
Symptoms: At presentation, the most common complaint was pain in 89.9% (268) 
followed by itching in 8.7% (26), and burning in 1.3% (4). Those who were 
asymptomatic accounted for 8.4% (25). 
The mean duration of symptoms was 6 days (Interquartile range: 5 to 7 days) . 
Signs: Erythema surrounding the lesions was noted in 67.5%, induration in 12.1%, 
locoregional lymphadenopathy in 8.3%, lymphangitis in 6.7%, necrotic changes in 6.7% 
and fever in 2.8% patients at the time of evaluation. 
 
Clinical types: The primary pyodermas included furuncles and other deep folliculitis in 
49.1% (115/234) followed by non-bullous impetigo in 14.1% (33/234), abscess in 13.6% 
(32/234), superficial folliculitis of Bockhardt in 11.1% (26/234), bullous impetigo in 
3.4%(8/234), and carbuncles in 1.3%(3/234). Other primary pyodermas included 
cellulitis, ecthyma, otitis externa and acute paronychia. 
 
Among secondary pyodermas, secondarily infected eczemas accounted for 37.1%, 
followed by ulcers (29.03%) and secondarily infected pemphigus (14.5%). Others 
included secondarily infected psoriasis, post-operative wounds and toxic epidermal 
necrolysis. 
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Sites of involvement: The lower extremities was found to be the commonest site for a 
primary or secondary pyoderma (27.8%), followed by head and neck in 21.8%, 
disseminated in 20.7%, trunk in  20.4%, upper extremities in 8.7%. The axillae and 
groins were relatively less common sites to be involved. 
 
Size of largest active lesion: The size of the largest active lesion in primary pyodermas 
was measured and most of them were found to be 5-10mm in size (36.3%, 85/234), while 
1-2 cms size was noted in 28.6% (67/234), 2-5 cms in 19.2% (45/234) and 4.3% (10/234) 
had lesions larger than 5 cms. 
 
Number of lesions:  Lesion count was performed for primary pyodermas. 49.6% of 
patients had 2-5 lesions, 19.6% had 6-10 lesions, 19% had solitary lesions and 11.6% had 
more than 10 lesions. 
  
 
 
Epidemilogic classification of Methicillin-resistant Staphylococcus aureus 
pyodermas: 
 
 
Majority of the MRSA pyodermas 92.6% (50/54) were sub-classified as CA-MRSA and 
the remaining 7.4% (4/50) as HA-MRSA. For the comparative analysis, we considered 
the differences among all MRSA versus MSSA pyodermas and not as per the sub-
classification. 
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 Comparative demographic and clinical profile of patients with MSSA and MRSA 
 
 
Table 6: Comparative demographic profiles of patients with MSSA and MRSA pyodermas 
 
Variable MSSA(N=144) 
n(n/N%) 
MRSA(N=54) 
n(n/N%) 
p-value 
Gender 
Male 
Female 
 
98(74.8) 
46(69.7) 
 
34(25.2) 
20(30.3) 
 
0.503 
 
Age 
<5 years 
>5 years 
 
25(65.8) 
119(74.4) 
 
13(34.1) 
41(25.6) 
 
0.285 
Facilities of residence 
Overcrowding 
No overcrowding 
 
37(57.8) 
107(79.9) 
 
27(42.2) 
27(20.1) 
 
0.001 
Socioeconomic status 
Upper 
Middle 
Lower 
 
17(80.9) 
104(78.2) 
23(52.3) 
 
4(19.1) 
29(21.8) 
21(47.7) 
 
 
0.002 
Contact sports 
Yes 
No 
 
10(66.7) 
134(73.2) 
 
5(33.3) 
49(26.8) 
 
0.584 
Medical comorbidities 
Yes 
No 
 
25(69.4) 
119(74.1) 
 
11(30.6) 
43(25.9) 
 
0.680 
 
Demographic factors associated with MRSA infection as compared to MSSA were 
overcrowding (p<0.0001) and low socioeconomic status (p=0.002). Genders and age-
groups were similar in their association with both MSSA and MRSA.  
 
The occurrence of MRSA in those with history of contact sports was not statistically 
significant (p=0.584). 
 
There was no significant association of MSSA or MRSA with co-morbid medical 
illnesses (p=0.680). 
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Table 7: Comparative antibiotic exposures among patients with MSSA and MRSA pyodermas 
 
Variable MSSA(N=144) MRSA(N=54) p-value 
Systemic antibiotic exposure 
≥2 antibiotics 
0-1 antibiotic 
 
33(52.4) 
111(82.2) 
 
30(47.6) 
24(17.8) 
 
 
<0.0001 
β-lactam exposure 
Yes 
No 
 
31(51.7) 
113(81.9) 
 
29(48.3) 
25(18.1) 
 
<0.0001 
Macrolide 
Yes 
No 
 
4(20) 
140(78.7) 
 
16(80) 
38(21.3) 
 
<0.0001 
Topical antibiotic exposure 
Yes 
No 
 
13(59.1) 
131(74.4) 
 
9(40.9) 
45(25.6) 
 
0.128 
 
The association of MRSA with exposure to two or more systemic antibiotics was found 
to be strongly significant (p<0.0001). Prior exposure to β-lactam antibiotics or macrolides 
in the past 1 year was significantly associated with MRSA pyodermas (p= <0.0001). 
Topical antibiotics were not associated similarly with MRSA (p=0.128). 
 
Table 8: Comparative history of prior pyodermas in patients with MSSA and MRSA pyodermas 
 
Variable MSSA(N=144) MRSA(N=54) p-value 
History of recurrent pyodermas or 
household clusters of infection 
Yes 
No 
 
 
29(50.9) 
115(81.6) 
 
 
28(49.1) 
26(18.4) 
 
 
<0.0001 
History of prior pyoderma 
First episode 
Recurrent episodes 
Multiple espidoses 
 
96(84.2) 
20(64.5) 
28(52.8) 
 
18(15.8) 
11(35.5) 
25(47.2) 
 
<0.0001 
 
MRSA pyodermas were significantly high in those with history of recurrent pyodermas 
or household clusters of infection (p=<0.0001).  
The prevalence of MRSA was significantly increased among the patients with multiple 
(35.5%) or recurrent pyodermas (47.2%) as compared to those with first episode (15.8%) 
of pyoderma (p<0.0001). 
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Table 9: Comparative clinical profiles of patients with MSSA and MRSA pyodermas 
 
Variables MSSA (N=144) MRSA(N=54) p-value 
Type of pyoderma 
Primary 
Secondary 
 
117(70.1) 
27(87.1) 
 
50(29.9) 
4(12.9) 
 
0.050 
Type of primary pyoderma 
Superficial folliculitis 
Furuncles 
Carbuncle 
Abscess 
Impetigo(non-bullous) 
Bullous impetigo 
 
14(100) 
58(64.4) 
0(0.0) 
12(57.1) 
22(84.6) 
6(100) 
 
0(0.0) 
32(35.6) 
3(100) 
9(42.9) 
4(15.4) 
0(0.0) 
 
 
Clinical features    
Surrounding erythema 
Yes 
No 
 
101(68.2) 
43(86.0) 
 
47(31.8) 
7(14.0) 
 
0.015 
Lympadenopathy 
Yes 
No 
 
11(68.8) 
133(73.1) 
 
5(31.3) 
49(26.9) 
 
0.709 
Lymphangitis 
Yes 
No 
 
7(38.9) 
137(76.1) 
 
11(61.1) 
43(23.9) 
 
0.001 
Induration 
Yes 
No 
 
14(51.9) 
130(76.0) 
 
13(48.2) 
41(24.0) 
 
0.009 
Necrotic changes 
Yes 
No 
 
6(50.0) 
138(74.2) 
 
6(50.0) 
48(25.8) 
 
0.068 
Fever 
Yes 
No 
 
0(0.0) 
144(75.4) 
 
7(100.0) 
47(24.6) 
 
<0.0001 
Site 
Head and neck 
Upper extremities 
Lower extremities 
Trunk 
Groins 
Palms/Soles 
Axillae 
Genitalia 
Disseminated 
 
29(78.4) 
11(55.6) 
38(82.6) 
27(69.2) 
1(100) 
- 
1(100) 
- 
37(68.5) 
 
8(21.6) 
9(45.4) 
8(17.4) 
12(30.8) 
0(0.0) 
- 
0(0.0) 
- 
17(31.5) 
 
Size 
≤ 2 cms 
>2 cms 
 
86(71.7) 
35(74.5) 
 
34(28.3) 
12(25.5) 
 
0.848 
Number of lesions 
Single lesion 
2-5 lesions 
6-10 lesions 
>10 lesions 
 
14(12.3) 
65(57.0) 
21(18.4) 
14(12.3) 
 
8(17.0) 
25(53.2) 
13(27.7) 
1(2.1) 
 
 
0.129 
Panton-Valentine leucocidin 
PVL+ 
PVL- 
 
21(72.4) 
35(58.3) 
 
8(27.6) 
25(41.7) 
 
0.197 
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Primary pyodermas were significantly associated with MRSA compared to secondary 
pyodermas (p=0.050). 
 
The prevalence of MRSA in deep pyodermas like furuncles, abscesses and carbuncles 
was more than those in superficial pyodermas like impetigo or superficial folliculitis. 
These differences were not statistically relevant because of disproportionate frequencies 
of individual types of primary pyodermas. 
 
Clinical signs like surrounding erythema (p=0.015), induration (p=0.009), lymphangitis 
(p=0.001) and fever (p=<0.0001) were significantly associated with MRSA, while 
necrotic changes (p=0.068) and lymphadenopathy (p=0.709) were not found to be 
statistically significant. 
 
Lesions over the upper limbs, disseminated disease and trunk had a prevalence of 45.4% 
31.5% and 30.8% respectively of isolation of MRSA, while the rest had relatively lower 
rates of isolation of MRSA.  
 
Size and number of lesions were not significant associations for MRSA pyodermas. 
  
Results of genotypic characterization of Staphylococcus aureus for PVL (Table 9) : 
 
PCR for PVL gene analysis was done in 88 retrieved S.aureus isolates. PVL carriage was 
found 29 in isolates and absent in 59 isolates. Among the PVL positive strains, 27.6% 
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(8/29) isolates were MRSA and 72.4% (21/29) were MSSA. All the PVL+ MRSA were 
CA-MRSA strains. There was no significant association between MRSA and PVL 
carriage, and was found to be present in both MSSA as well as MRSA (p=0.174). None 
of the HA-MRSA isolates were found to be positive for PVL carriage. 
 
 
Factors associated with increased risk for PVL associated S.aureus pyodermas: 
 
 
Table 8: Comparative demographic profiles of PVL positive S.aureus and PVL negative S.aureus:  
 
Variables PVL negative 
(N=59) 
PVL positive 
(N=29) 
p-value 
Occupation 
Pre-school children 
School children 
College students 
Manual labourers 
Health-care workers 
Others 
 
16(76.1) 
9(56.2) 
4(44.4) 
5(62.5) 
3(42.9) 
22(81.5) 
 
5(23.9) 
7(43.8) 
5(55.6) 
3(37.5) 
4(57.2) 
5(18.5) 
 
Facilities of residence 
Overcrowding 
No overcrowding 
 
19(61.3) 
40(70.2) 
 
12(38.7) 
17(29.8) 
 
0.429 
SES 
Upper 
Middle 
Lower 
 
4(57.1) 
41(70.7) 
14(60.9) 
 
3(42.9) 
17(29.3) 
9(39.1) 
 
0.622 
 
 
Although 17/29 PVL positive S.aureus were isolated from children and young adults 
(age<30 years), there was no statistically significant difference among the various age 
groups (p=0.477).  
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Table 9: Comparative clinical profiles of PVL positive S.aureus and PVL negative S.aureus 
 
Variables PVL negative 
(N=59) 
PVL positive 
(N=29) 
p-value 
Type of pyodermas 
Primary 
Secondary 
 
54(66.7) 
5(71.4) 
 
27(33.3) 
2(28.6) 
 
0.780 
Type of primary pyodermas 
Superficial(others) 
Deeper(furuncles/carbuncles/abscess) 
 
17(77.3) 
32(57.1) 
 
5(22.7) 
24(42.9) 
 
0.123 
Clinical features    
Necrotic changes 
Yes 
No 
 
1(12.5) 
58(72.5) 
 
7(87.5) 
22(27.5 
 
0.001 
Induration 
Yes 
No 
 
7(50.0) 
52(70.3) 
 
7(50.0) 
22(29.7) 
 
0.139 
Lymphangitis 
Yes 
No 
 
7(53.9) 
52( 69.3) 
 
6(46.1) 
23(30.7) 
 
0.273 
Surrounding erythema 
Yes 
No 
 
47(64.4) 
12(80.0) 
 
26(35.6) 
3(20) 
 
0.241 
Size 
<2 cms 
>2 cms 
 
42(72.4) 
17(56.7) 
 
16(27.6) 
13(43.3) 
 
0.136 
Site 
Head and neck 
Upper extremities 
Lower extremities 
Trunk 
Groins 
Palms/Soles 
Axillae 
Genitalia 
Disseminated 
 
12(75.0) 
3(37.5) 
14(77.8) 
10(66.7) 
1(100) 
- 
1(100) 
- 
18(62.1) 
 
4(25.0) 
5(62.5) 
4(22.2) 
5(33.3) 
0(0.0) 
- 
0(0.0) 
- 
11(37.9) 
 
 
 
The clinical features were tested for PVL association and only necrotic changes were 
found to be a significant association (p=0.001).  
 
Pyodermas like furuncles, carbuncles or abscesses were noted to have PVL positive 
S.aureus in 42.9%; however the association was not statistically significant (p=0.123).  
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DISCUSSION 
 
Pyodermas constitute a significant burden of cutaneous diseases across the world, and 
more significantly, in the tropical countries.(102) Majority of these are caused by 
Staphylococcus aureus. In contrast with high-income countries, S.aureus disease ranks 
low on the public-health agenda in developing and underdeveloped countries. However, 
neglected status as a developing world pathogen does not equate with low rates of 
disease.(106) The prevalence of methicillin-resistant S.aureus (MRSA) infection across 
much of resource-limited Asia including India is largely unknown. There are few 
prospective studies from India on the prevalence of MRSA in community-associated 
pyodermas, the presence of virulence factors like Panton-Valentine leucocidin and risk 
factors associated with the same.(12)(49) The prevalence of MRSA has been as variable 
as less than 1% to 9.6% from dermatology  outpatient based studies from India(12)(49), 
which contradicts with pilot data in our institution revealing 27% S.aureus to be 
methicllin-resistant in pyodermas. These lacunae and discrepancies in existing data 
prompted us to undertake a prospective cross-sectional study to address these key issues. 
 
The prevalence of S.aureus was found to be maximum among all bacteriae isolated from 
SSTIs (77.3%) in our study as was described in other studies as well. (20)(25) Of the 
S.aureus isolates, 27.3% (54/198) were found to be methicillin-resistant. CA-MRSA 
accounted for 92.6% (50/54) and HA-MRSA for 7.4% (4/54) of the MRSA strains 
isolated. Del Guidice et al.(5) demonstrated 11% (22/197) of MRSA from 197 isolates of 
S.aureus from primary and secondary pyodermas. Of the 22 MRSA isolates in the same 
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study, 6 were classified as CA-MRSA,15 as HA-MRSA and 1 as MRSA strain of 
unknown origin. Jappe et al.(4) demonstrated 52.4% (130/248) of all pyodermas 
presenting to a tertiary care university hospital in Heidelberg, Germany, to be associated 
with S.aureus, with 7.3%(18/130) of all S.aureus isolates being methicillin-resistant. Out 
of 18 isolates of MRSA in the Heidelberg study, 4 were sub-classified as CA-MRSA. 
For our study, we limited ourselves to the definitions of CA-MRSA and HA-MRSA, 
provided by Salgado et al.(36), which is the same as that adopted for 
clinicians(CDC,2005). (52) By this criteria the majority of patients were CA-
MRSA(50/54, 92.6%). Our study included 9.2% of healthcare-workers, who could 
possibly be circulating HA-MRSA strains, but were not included under the HA-MRSA 
group as per the criteria used.  This criteria was also used in outpatient studies by Del 
Guidice(5) and Jappe et al.(4) On the other hand, prior Indian studies have used the 48 
hour post-admission nosocomial isolates of MRSA as HA-MRSA, thereby assuming all 
outpatient cases to be community-associated; hence the prevalence data are not 
comparable due to use of different set of criteria. Conversely, CA-MRSA can be acquired 
in the hospital as well, due to increasing prevalence of CA-MRSA. Given the complex 
epidemiology of CA-MRSA strains in health care settings and the circulation of HA-
MRSA strains that occurs in the community, establishing a clear delineation between CA-
MRSA and HA-MRSA strains has not been possible. CDC investigators have used a third 
category of MRSA infections, "health care-associated, community-onset" MRSA 
(HACO-MRSA) infection (107); this category includes cases that would be HA-MRSA 
infections by history of health care exposure but have onset in the community. This 
tripartite classification scheme, HA-, CA-, and HACO-MRSA, still has limitations 
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because a history of exposure to a health care setting does not exclude the possibility of 
MRSA acquisition and infection in the community.  
 
It was interesting to note that more than 30% (85/298) of the total study population in our 
study included children below 16 years. In a pediatric cohort of pyodermas studied by 
Sardana et al.(48) in New Delhi, the prevalence of MRSA was only 6.9%, while our 
study showed a prevalence of 35.2% (19/54).  
 
There was no occupation showing an increased association with MRSA. Other 
occupations that are known to have high prevalence of MRSA pyodermas like military 
recruits, professional athletes, veterinarians or meat handlers (15)(22) were not 
encountered in our study. MRSA infection was not significantly associated among health-
workers in our study. In a study by Reich-Schupke et al.(103) conducted at a dermatology 
department in Germany, both patients and employees of the department were 
prospectively enrolled to study nasal carriage of MRSA The nasal carriage between 
hospital employees and outpatients was not significant(108). Although the presence of 
PVL in HA-MRSA is characteristically not seen (4)(107), nosocomial transmission of 
PVL-carrying MRSA leading to fatality in a healthcare worker has been reported.(109) 
This could imply CA-MRSA strains being spread to health-care workers in the hospital. 
 
The demographic factors significantly associated with MRSA in our study were 
overcrowding and low SES. Our study showed 29.4% (87/298) of the study population 
living in overcrowded spaces. These patients were more susceptible to developing 
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pyodermas as a result of poor hygiene, fomite spread and direct spread in household 
clusters of pyodermas in overcrowded environments. (87)(110) Although overcrowding 
has particularly not been described in earlier studies to be an epidemiological association 
of MRSA, there is indirect evidence of the same. Pallin et al(87) have suggested that the 
higher isolation of MRSA from EDs in USA could be possibly because of patients 
presenting from low SES and staying in overcrowded places.(110) Underserved urban 
communities have been found to be risk factor for MRSA carriage in the US or 
developing countries like Nigeria.(22)(102) There are no other studies that have assessed 
socioeconomic status by a scoring system to determine prevalence of CA-MRSA.  
 
A prior retrospective study at our center in 1996 by Pulimood et al. showed 24% of all 
S.aureus isolates from blood or pus to be methicillin-resistant.(40) However, the study 
did not however elaborate on prevalence of MRSA in SSTIs or the proportion of 
nosocomial isolates separately. Studies from other centres in India have shown variable 
prevalence rates of 11.8% in Mangalore(11), 9.6% in New Delhi(49) and 0.9% in 
Mumbai.(12) In our sudy, the overall prevalence of MRSA in any pyoderma was 18.1%, 
while MRSA among all S.aureus isolates was 27.3%. These figures were higher than 
other available reports from India.  
 
Bae et al(9) demonstrated high prevalence of PVL positive S.aureus across the world. 
Goering et al (21) showed PVL positive stains (2 PVL+ MRSA, 15 PVL+ MSSA) from 
India among other centers in a multicentric study. A cohort of miscellaneous CA-MRSA 
and HA-MRSA(111) PVL positive strains were reported by Nagarajan et al(66) from 
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Chennai. In a study by Nadig at al (67) from Bangalore, nasal swabs from patients with 
SSTIs, brain abscesses and meningitis showed PVL positive S.aureus isolates. PVL 
positive isolates have been reported in genotyped S.aureus from Mumbai by D’Souza et 
al.(111) PVL positive MRSA has been isolated in an adolescent from Chennai with 
furuncles, sepsis and pneumonia.(17) PVL positive S.aureus patients in our study were 
isolated from patients belonging to the states of Tamilnadu, Karnataka, Andhra Pradesh, 
West Bengal, Jharkhand, Tripura from India and a single patient from Bhutan. This 
reveals the emergence of PVL positive S.aureus in the Indian subcontinent. Further 
characterization of strains is needed to determine if they are similar to other clones from 
rest of the world. 
 
Although diabetes, hypertension, dyslipidemia, obesity were noted in a few patients, 
there was no statistically significant association seen. Diabetes(4)(112), obesity(103) and 
chronic leg ulcers(4)(108) have been described for increased carriage of MRSA and PVL. 
Due to the small numbers of S.aureus isolates from immunosuppressed patients, an 
association with MRSA could not be ascertained. 2 patients with atopic dermatitis were 
found to have MRSA infection. Lo et al. (59) demonstrated increased carriage of MRSA 
in atopic dermatitis in a cohort of Taiwanese children.  
 
Various studies have shown prior exposure to systemic antibiotics to be associated with 
acquisition of MRSA. (4)(15)(94)(113) This was also seen in our study.  
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The association of recurrent pyodermas or household clusters of infection was found to 
be significantly associated with MRSA isolation. This risk factor has also been described 
widely in prior studies. (16)(22) (24)(36)(80)(110)  
 
There was a statistically significant difference of MRSA being more prevalent in the 
primary pyoderma group. Most prospective studies have not evaluated this difference in 
MRSA epidemiology. MRSA has been described in primary infections like cutaneous 
abscesses, furuncles(5)(8) as well as diabetic foot ulcers(112), atopic dermatitis(61) and 
chronic venous leg ulcers.(4)(108) Among secondary pyodermas, we did not differentiate 
between infection and colonization as mentioned in the methodology. 
 
Cutaneous infections like furuncles, abscesses and carbuncles were associated with 
higher rates of MRSA isolation as compared to other pyodermas. Complicated 
pyodermas like pyomyositis, necrotizing fasciititis were not encountered in the study. 
There were few cases of felon/acute paronychia for statistical comment.  
 
There was no statistically significant association between CA-MRSA and PVL, as PVL 
was found commonly among MSSA(36.4%) as well as MRSA(24.2%) in our study. 
MSSA actually had nearly 14% increased prevalence of PVL among the isolates 
subjected to PCR analysis. None of the isolates sub-classified as HA-MRSA were 
positive for PVL. 
Contrary to earlier studies(5)(8) that have suggested PVL to be an epidemiological 
marker of CA-MRSA, our study shows PVL to be a marker of community associated 
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strains of S.aureus, irrespective of their methicillin-resistance status. PVL positive MSSA 
has been particularly noted to be of higher prevalence in South Africa and India by 
Goering et al. (21) Hence, it is possible that in India, the prevalence of PVL in MSSA is 
higher than described in other European studies.  
 
The only significant association of PVL in this study was necrotic changes associated 
with staphylococcal pyodermas. Dermatonecrotic property of PVL has been described in 
several reports and studies (22)(70) because of which it has been confused with spider-
bites. Jappe et al.(4) noted younger patients and deep skin infections to be associated with 
PVL infections. Our study did not show any such statistically significant correlation 
although 17/29 PVL isolates were seen among children and young adults below 30 years 
of age. 
Higher prevalence of MRSA and PVL individually in primary infections like 
furunculosis and abscesses is in concurrence with other studies. (5)(8) PVL is also not 
necessarily and universally associated with all deep infections like abscesses or furuncles 
and contradicts earlier studies.(7)(8) This is supported by more recent studies of similar 
designs(4)(56)(57) that PVL is not necessarily a part of all deep infections. MRSA may 
be associated significantly with more severe infections but still are clinically 
indistinguishable (95) as MSSA can also manifest with similar manifestations. 
This prospective study on pyodermas had a larger sample size than prior studies of 
similar interest (4)(5) and design done elsewhere in the world. There is no prior published 
data from India on the associations of MRSA and PVL carriage. In summary, S.aureus is 
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the most common implicated organism in SSTIs with a prevalence of 66.4%. MRSA 
prevalence (27.3%)in our study was higher compared to other published Indian studies. 
(11)(12)(49) Demographic risk factors in Indian subjects for MRSA are similar to those 
in earlier described studies like overcrowding, low socio-economic status, recurrent 
infections or household clusters of infection and prior systemic antibiotic use like β-
lactams and macrolides.  
 
Our study demonstrated association of low SES with MRSA infections for the first time, 
using a standard scoring system. We also note that PVL did not correlate with 
methicillin-resistance; however larger studies are needed from India to correlate between 
PVL and S.aureus pyodermas, its association affecting antimicrobial susceptibility and 
association with outcome of disease. 
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CONCLUSIONS 
 Staphylococcus aureus was the most common organism (66.4%) isolated from 
primary or secondary pyodermas. 
 The prevalence of MRSA among all pyodermas was 18.1% and among all 
S.aureus pyodermas was 27.3%. This prevalence was higher compared to prior 
studies done from India in the past(41)(48)(50) or in the contemporary 
period(11)(49). CA-MRSA was noted in 92.6% of all MRSA pyodermas.  
 Significant associations for increased risk of MRSA pyodermas in this study were 
overcrowding, low SES, recurrent pyodermas or household clusters of infection 
and prior exposure to systemic antibiotics like β-lactams and macrolides. 
 Primary pyodermas are more often associated with MRSA than secondary 
pyodermas. Primary pyodermas with surrounding skin erythema, induration, 
lymphangitis and fever were significantly associated with MRSA. 
 Panton-Valentine leucocidin carrying S. aureus are prevalent in India, across 
different geographical areas. They were however, not significantly associated 
with MRSA and were seen more commonly among MSSA strains. PVL 
expression was not seen among isolates with hospital-associated risk factors. 
 PVL, a dermatonecrotic toxin was significantly associated with necrotic skin 
changes. 
 Our data suggests continued surveillance of MRSA among dermatology 
outpatients as dermatologists are first in line to note the changing epidemiology of 
S.aureus. 
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Limitations 
 Presence of PVL in all isolates of S.aureus would allow a better estimate of its 
association with SSTIs. 
 
 Follow up among these patients was not part of this cross-sectional study; hence a 
correlation of management and outcome could not be studied. 
 
 Anti-microbial susceptibility besides for oxacillin and erythromycin was not 
uniformly studied among the S.aureus isolates. 
 
 
Future directions 
 
 Antimicrobial studies on PVL positive and negative strains will help in 
determining if there is any significant difference in their susceptibility profiles. 
 
 The emergence of PVL among S.aureus in the Indian subcontinent is now 
established. Further studies can be done to look for clonality of these strains in 
comparison to those isolated in other parts of Asia or Europe. 
 
SUMMARY 
 
Background: Methicillin-resistant Staphylococcus aureus (MRSA), a known nosocomial 
pathogen, has been increasingly reported globally in patients from the community, 
without hospital-related risk factors. Pyodermas represent majority of the disease burden 
caused by MRSA. Community associated-MRSA (CA-MRSA) and methicillin-
susceptible S.aureus (MSSA) may harbour Panton-Valentine leucocidin (PVL) which is 
associated with necrotic and severe infections. There is no published data on 
demographic and clinical features of MRSA and PVL associated pyodermas from India. 
 
Objective: To study the clinical and microbiological features of S.aureus pyodermas, and 
evaluate association of demographic and clinical factors with MRSA and PVL. 
 
Methodology: An open, prospective, cross-sectional study was carried out in the 
Department of Dermatology, Venereology and Leprosy, Christian Medical College and 
Hospital, Vellore from July 2009 to July 2010 for patients presenting with pyodermas. 
Pus cultures were obtained by standard methods and S.aureus isolates were further 
characterized for MSSA and MRSA phenotypically and genotypic characterization for 
presence of PVL was done by PCR.  
 
Results: 298 patients (184 males, 114 females) were enrolled into the study. S.aureus 
was the most commonly isolated organism 66.4% (198/298). Among all S.aureus, 27.3% 
(54/198) were MRSA. CA-MRSA accounted for 92.6% (50/54) of MRSA, as per CDC 
classification criteria for clinicians. 29.5% (88/298) of patients were in the pediatric age-
group. The majority of patients had primary pyodermas 78.5% (234/298), with the rest 
being secondary pyodermas (21.5%). Furuncles (49.1%) and non-bullous impetigo 
(14.1%) were the most common presentations among primary pyodermas. Demographic 
factors associated with MRSA infection as compared to MSSA were overcrowding 
(p<0.0001) and low socioeconomic status (p=0.002). The association of MRSA with 
exposure to two or more systemic antibiotics (p<0.0001), prior exposure to β-lactam 
antibiotics or macrolides in the past 1 year (p= <0.0001) and those with history of 
recurrent pyodermas or household clusters of infection (p=<0.0001) was significant. 
Primary pyodermas were significantly associated with MRSA compared to secondary 
pyodermas (p=0.050). The prevalence of MRSA in deep pyodermas like furuncles, 
abscesses and carbuncles was more than those in superficial pyodermas like impetigo or 
superficial folliculitis. Clinical signs like surrounding erythema (p=0.015), induration 
(p=0.009), lymphangitis (p=0.001) and fever (p=<0.0001) were significantly associated 
with MRSA. There was no significant association between MRSA and presence of PVL 
(p=0.174). None of the HA-MRSA isolates were found to be positive for PVL carriage. 
Necrotic changes in primary pyodermas were found to be significantly associated with 
PVL (p=0.001).  
 
Conclusion: The prevalence of MRSA in this study was higher compared to other studies 
from India. PVL positive S.aureus are prevalent in India and were isolated in both MSSA 
and MRSA. Further studies are required on larger populations from India to study 
association of PVL with antimicrobial susceptibility and outcome of disease. 
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Annexure I. 
 
Informed Consent form to participate in a research study  
Study Title: To study the clinico-microbiological profile of Staphylococcus aureus in 
Dermatology outpatients 
 
Study Number: 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
Please initial box  
(Subject) 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look at my 
health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I 
understand that my identity will not be revealed in any information released to third parties or 
published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such 
a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
 
 
 
 
STUDY INFORMATION SHEET 
 
1) Explanation of  the purpose of the research 
A research study is a special way to find out about something.  It is a common to see patients 
coming to Dermatology with pus or boils on the skin. The medicines that are used may not work at 
times since the bug causing the infection may be resistant to it. The bug’s resistance can be known 
by a culture and sensitivity test which takes about three days. I intend to find predictors that will 
help doctors decide when the skin infection might be caused by a resistant bug called MRSA 
This study also involves finding a certain factor in these bugs called PVL which is known to 
increase the severity of the infection. There is no information in India whether this factor 
exists or not in the bugs. If this factor is common and study shows significant problems 
because of it, this could be offered as a diagnostic test in the hospital. Knowledge of these 
factors and resistance patterns will help us treat patients better.  
2) Expected duration of the subject’s participation: 
We will see you only once in the study period 
3) Procedures to be followed, including invasive procedures: 
The doctor will do detailed clinical examination and note down the data in a special 
proforma.  We will collect pus with swabs for further tests, which is part of your regular 
care. We may perform incision and drainage (involves a small cut on skin) or puncture 
the pus collection with a needle and aspirate pus. 
4) Any reasonably foreseeable risks or discomforts to the subjects 
We want to tell you about somethings that might hurt or upset you if you are in this 
study. 
The most common side effects from incision and drainage/sterile aspiration include: 
 Pain 
 Bleeding 
5) Any benefits to the subject. 
Any method to drain the pus has therapeutic benefit and this procedure is also done for 
diagnosing which bug is causing your problem, and which all drugs can be used to treat the 
infection.  
6) Disclosure of specific appropriate alternative procedures or therapies: 
Not applicable 
7) Confidentiality of records 
Every reasonable effort will be made to keep your records confidential, However, while you 
are in this study we do have to let some people look at your records.  The IRB ( for the 
protection of human subjects in research), other regulatory agencies responsible for 
overseeing research (if applicable) and the co-investigators. We will keep your records 
confidential unless we are required by law to share any information. 
8) Trial treatment schedules:  not applicable 
9) Compensation and /or  treatment(s) available to the subject in the event of a trial 
related injury: 
       Not applicable 
10) Nature of participation in the study: 
It is not compulsory for you to participate in the study. It’s up to you. If you even decide to 
withdraw from the study later at any point of time you are eligible to do so. All that you 
have to do is to tell us. Your refusal to participate in the study will not involve any penalty 
or would not affect your treatment in any aspect, you can continue your treatment here as 
before. 
Annexure 2.  Proforma for Clinico-microbiological profile of Staphylococcus aureus 
 in Dermatology outpatients 
 
Socio-demographic data 
 
 
 
Patient name:                                    Hospital No:                              Study ID no: 
Age:                                 Neonate/Infant/1- 2 yrs/2-4 yrs/5-15 yrs/16-60 years/> 60 years 
Occupation:                            Pre-school/Students(school)/Students(college students or 
higher education)/professional atheletes /military personnel/manual labourer/others 
Place of stay:                                       In Vellore/ Rest of Tamil Nadu/Others 
Facilities of residence:                              Single room/shared room with one/shared with 
more than one/overcrowding 
History of contact sports:                             High risk behaviour: Y/N   Sexual 
orientation:                               
History of hospitalization, receipt of hemodialysis, or residence in a long-term care 
facility during the previous year; surgery during the previous one year ; the 
presence of an indwelling catheter or a percutaneous device at the time the culture 
sample was obtained; or previous isolation of MRSA: 
History of medical comorbidities:                            
diabetes/hypertension/hypothyroidism/dyslipidemia/obesity/immunocompromised/on 
immunosuppresants/others(_________________________) 
History of recurrent(twice or more in six months) primary pyodermas or household 
clusters of infection:  yes/no/ history not reliable 
History of poor response to beta-lactam antibiotics:          yes/no/ history not reliable 
History of exposure to two or more groups of antibiotics in the past one year:   
yes/no/history not reliable 
If yes, what antibiotics:     beta-lactams/quinolones/macrolides/___________________ 
Topical antibiotics______________________ 
History of recent travel:        yes/no                If yes, to:      
Education status of family member( highest in the family): 
Professional or honors(7)/graduate or postgraduate(6)/intermediate or post-high school 
diploma(5)/high school certificate(4)/middle school certificate(3)/primary school 
certificate or literate(2)/illiterate(1) 
Occupation status:  
profession(10)/semi-profession(6)/clerical,shop owner,farmer(5)/skilled worker(4)/semi-
skilled worker(3)/unskilled worker(2)/unemployed(1) 
Family income per month: 
(in Rs. Per month) >/= 19575(12)/19574-9788(10)/9787-7323(6)7322-4894(4)/4893-
2936(3)/2935-980(2)/<980(1) 
Score: 
Socioeconomic status:  
Upper(26-29)/ Upper middle(16-25)/Lower middle(11-15)/Upper lower(5-10)/Lower(<5) 
 
 
Clinical proforma 
 
Duration of Symptoms: 
History of pyoderma-First episode/Multiple episodes but six months apart/recurrent 
episodes: 
If recurrent or multiple: what was the type of pyoderma earlier: 
History of symptoms: pain/ burn/itch/asymptomatic/others 
 
Clinical syndrome:   
Primary pyoderma:  
 
Morphological 
type of lesion 
Site/s  Size  Number  Surrounding 
erythema  
Induration Necrotic 
changes 
Lymphangitis  Lymphadeno
pathy  
Fever  
          
          
          
          
          
          
          
 
 
 
 
Secondary pyoderma: 
Primary diagnosis: 
 
Additional Information: 
 
 
Microbiological data: 
 
Bacteria isolated:________/__________/__________/__________/_____________ 
If S.aureus: 
 
MSSA/MRSA: 
PVL: positive/negative 
hospno pvl name age agecategoryoccupation otheroccupationplaceofstay facilitiesofresidenceconta tsportshighriskbehaviorsexualorientationmedicalcomorbiditieshamrsari kfactorsothercomorbidillnesseshistoryofr currentpyodermasorhouhistoryofpoo resp nsetobetalactahistoryofpo rr sponsetoantibiotantibiotic xposure
000757c 0 Indrakala 29 6 8 housewife 1 3 0 0 0 7 1 0 0 0 0 0
003803D 1 Jayashanker 42 6 7 0 2 1 0 0 0 1 0 0 0 0 0 0
006116D 0 Hamshavarshini 52 6 8 housewife 1 1 0 0 0 0 1 0 0 1 0 0
011298B 0 Hemalatha 50 6 8 housewife 1 3 0 0 0 1 0 0 0 0 0 0
014284B 0 bALKISH 28 6 3 0 1 4 0 0 0 7 0 CBDC 0 0 0 0
025797B 1 pRABHAKAR 38 6 7 0 1 2 0 0 0 0 0 0 0 0 0 0
029608D 0 sHEELA 23 6 3 0 2 1 0 0 0 0 0 0 0 0 0 0
038070C 0 Udaishanker 50 6 8 engineer 4 2 0 0 0 0 0 0 0 0 0 1
040699D 0 Vaigai's baby 3 4 1 0 1 4 0 0 0 0 0 0 0 1 0 0
052092D 0 Nitya 3 4 2 0 1 1 1 1 0 0 0 0 0 0 0 0
057325d 0 srinivasulu 73 7 8 retired teacher 4 1 0 0 0 1 0 0 0 0 0 0
058207D 0 Rajesh Martin 20 6 3 0 1 2 1 0 0 0 0 0 0 1 0 0
058522D 0 Sophia 34 6 7 0 1 3 0 0 0 0 0 0 0 0 0 0
061554B 0 Vellai 60 7 6 0 1 3 0 0 0 1 0 0 0 0 0 0
062851D 0 Prarthana 20 6 3 0 1 3 0 0 0 0 0 0 1 1 0 1
092089d 0 Sathiya's baby 1 3 1 0 1 3 1 0 0 0 0 0 1 0 0 0
092175D 0 Usha Rani's baby 2 3 1 0 1 4 0 0 0 0 1 0 0 0 0 0
115123D 0 Latha's baby 2 3 1 0 1 4 0 0 0 0 0 0 0 0 0 0
130677D 0 Latheef 38 6 6 0 1 4 0 0 0 1 0 0 1 0 0 1
130970C 0 Dhanusurya 8 5 2 0 1 3 1 0 0 0 0 0 0 0 0 0
133819D 0 Swapan Kumar 58 6 8 clerk 4 1 0 0 0 0 0 0 0 0 0 0
134261A 0 RUCKMANI 55 6 8 housewife 1 4 0 0 0 1 0 0 0 0 0 0
135923D 0 Sathiya's baby 2 3 1 0 1 4 0 0 0 0 0 0 0 0 0 0
136111D 0 Shanmugapriya 25 6 7 0 1 2 0 0 0 0 0 0 0 0 0 0
137501D 0 Merlin 2 3 1 0 1 3 0 0 0 0 1 0 0 0 0 1
158097C 0 Jim Evans 25 6 3 0 3 1 0 0 0 5 1 Hyper IgE 1 1 0 1
162064D 0 Parimals's baby 1 2 1 0 4 4 0 0 0 0 0 0 1 0 0 0
167203D 0 Gopinathan 29 6 8 clerk 1 3 0 0 0 0 6 0 1 0 0 1
172308D 1 Vijaylakshmi's baby 1 2 1 0 1 1 0 0 0 0 6 0 1 0 0 0
183171A 0 Mani 55 6 7 0 1 4 0 0 0 1 0 0 0 0 0 0
222296B 0 Maragathavalli 46 6 8 0 1 2 0 0 0 0 0 0 1 0 0 0
230816A 0 Manoharan 55 6 7 0 1 2 0 0 0 0 0 0 0 0 0 0
231846C 0 Pushpa's baby 7 5 2 0 2 4 1 0 0 0 0 0 1 1 0 1
238006B 0 Sadrack 2 3 1 0 1 3 0 0 0 0 6 0 0 0 0 0
238006b 0 Sadrack 12 5 2 0 1 3 1 0 0 0 0 0 0 0 0 0
240367D 1 Sarma 68 7 8 retired employee 4 2 0 0 0 1 0 0 0 0 0 0
247262C 0 Sweety 7 5 2 0 1 1 0 0 0 0 0 0 0 0 0 0
253549D 0 Kishori Lal 43 6 6 0 4 4 0 0 0 0 0 0 0 0 0 0
253868D 0 Amidhi's baby 1 2 1 0 1 1 0 0 0 0 0 0 1 0 0 0
258591D 0 Anant 44 6 8 grocer 4 2 0 0 0 0 0 0 0 0 0 0
261378A 0 Babu 27 6 7 0 1 3 0 0 0 0 0 0 1 0 0 0
267591B 0 Violet 57 6 0 housewife 2 3 0 0 0 1 0 0 0 0 0 1
268147D 0 Ebenezer 20 6 3 0 1 3 0 0 0 0 0 0 1 0 0 0
281981 0 Natarajan 46 6 8 0 1 2 0 0 0 0 0 0 0 0 0 0
282166D 0 Gomathi 22 6 7 0 1 3 0 0 0 0 0 0 0 0 0 0
295152D 0 Sibi Raj 1 2 1 0 1 4 0 0 0 0 0 0 0 0 0 0
299434D 0 Francis 52 6 8 clerk 4 1 0 0 0 7 1 Adenocarcinoma lung0 0 0 0
300486D 0 Elongovan 55 6 8 lawyer 1 2 0 0 0 7 1 pemphigus 1 0 0 1
309232 0 Lalitha 59 6 8 housewife 1 2 0 0 0 6 1 0 0 0 0 0
317719B 0 Ramraj 22 6 7 0 1 2 0 0 0 0 0 0 0 0 0 0
319980C 0 Selvaraj 52 6 6 0 1 3 0 0 0 0 0 0 0 0 0 1
320966C 0 Elizabeth Verghese 25 6 7 0 1 3 0 0 0 0 0 0 0 0 0 0
325767D 0 Vikash 17 6 2 0 4 1 0 0 0 0 1 tuberculosis 0 0 0 1
326618D 0 Lakshmi 42 6 8 housewife 1 1 0 0 0 0 0 0 1 0 0 1
329238D 0 Illayaraja 26 6 7 0 1 2 0 0 0 0 0 0 0 0 0 0
332235D 1 Nilesh 20 6 3 0 4 2 0 0 0 0 0 0 0 0 0 0
340764D 0 Vikram 28 6 6 0 1 4 0 0 0 0 0 0 0 0 0 0
345682C 1 Dilip 7 5 2 0 4 3 0 0 0 0 0 0 0 0 0 0
347420D 0 Rajeshwari's baby 1 1 1 0 1 3 0 0 0 0 0 0 0 0 0 0
347440D 0 Kevin 1 2 1 0 1 3 0 0 0 0 0 0 0 0 0 0
347440d 0 Ammukutty's baby 1 3 1 0 1 3 0 0 0 0 0 0 0 0 0 0
35682c 0 Dileep 6 5 2 0 1 3 1 0 0 0 0 0 1 1 0 1
357124D 0 Raghupathy 36 6 6 0 1 4 0 0 0 0 0 0 0 0 0 0
364950D 0 Kanchan 44 6 1 0 4 2 0 0 0 0 0 0 0 0 0 0
367981D 0 Sumit 54 6 8 business 4 3 0 0 0 0 0 0 0 0 0 0
369066D 1 Karma Tenzin 15 5 2 0 4 4 0 0 0 7 1 ALL 0 0 0 0
369086D 0 Punitha 31 6 8 housewife 1 4 0 0 0 1 0 0 1 1 0 1
371365D 1 Yogeshwaran 1 2 1 0 2 4 0 0 0 0 0 0 1 0 0 0
372957D 0 Sultana's baby 1 1 1 0 1 4 0 0 0 0 0 0 0 0 0 0
376013D 0 Bijaya 45 6 8 housewife 4 2 0 0 0 7 1 CML 0 0 0 1
379688C 0 Bhuvaneshwari's baby6 5 2 0 1 4 1 0 0 0 0 0 1 0 0 1
380182A 0 Jeyaraman 59 6 6 0 1 2 0 0 0 0 0 0 1 1 0 1
385789D 0 Menaga's baby 1 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0
386223C 0 Manopriya 30 6 7 0 1 2 0 0 0 5 0 0 0 0 0 0
389271D 1 Abdul khader 1 1 1 0 1 4 0 0 0 0 0 0 0 0 0 1
392327D 0 Debasish 5 5 2 0 1 3 1 0 0 0 0 0 0 0 0 0
394666B 0 Balaji 30 6 6 0 1 2 0 0 0 0 0 0 0 0 0 0
395890C 1 Leela's baby 6 5 2 0 1 1 0 0 0 0 0 0 0 0 0 1
400700D 0 Khutaija's baby 1 2 1 0 1 4 0 0 0 0 0 0 0 0 0 0
403404D 1 Amit Bugalia 31 6 7 0 1 2 0 0 0 0 0 0 1 1 0 1
404600C 0 Shaikh Suban 6 5 2 0 4 4 1 0 0 0 0 0 1 0 0 1
408915C 0 Baby's baby 6 5 2 0 1 3 0 0 0 0 0 0 0 0 0 0
412364C 0 Rebeca 9 5 2 0 1 4 0 0 0 0 0 0 0 0 0 1
415873C 0 Nibil 45 6 8 business 4 2 0 0 0 0 0 0 0 0 0 0
428707D 0 Subrata 46 6 8 business 4 2 0 0 0 0 0 0 0 0 0 0
436643D 0 Sudhir 27 6 8 0 3 2 0 0 0 0 0 0 0 0 0 0
443303D 0 Harish 6 5 2 0 1 3 0 0 0 0 0 0 1 0 0 1
446540D 0 Sweta 23 6 3 0 1 2 0 0 0 0 0 0 0 0 0 0
448850C 0 Jayakumari 55 6 8 housewife 1 2 0 0 0 0 0 0 0 0 0 0
448850c 0 Jayakumari 55 6 8 housewife 1 2 0 0 0 0 0 0 0 0 0 0
450147D 0 Teja 5 5 2 0 4 4 0 0 0 0 0 0 0 0 0 0
451026B 0 Renugopal 36 6 7 0 1 2 0 0 0 0 0 0 0 0 0 0
451052D 0 Hannah 1 2 1 0 1 3 0 0 0 0 0 0 0 0 0 0
451355D 1 Lakshman Jana 33 6 6 0 4 4 0 0 0 0 0 0 0 0 0 0
451741C 0 Akhtar 48 6 8 housewife 1 4 0 0 0 0 0 0 1 0 0 1
451793D 1 Farjhaha 15 5 2 0 1 4 0 0 0 0 0 0 1 0 0 0
453621D 0 Ganesh 27 6 6 0 1 4 0 0 0 0 0 0 0 0 0 0
453621d 0 Ganesh 43 6 6 0 1 3 0 0 0 5 0 0 1 0 0 0
481555C 0 Fazil 5 5 2 0 1 4 1 0 0 0 0 0 1 0 0 1
481555C 0 Fazil 6 5 2 0 1 4 0 0 0 0 0 0 1 0 0 0
484343D 0 Devi's baby 1 2 1 0 1 3 0 0 0 0 0 0 0 0 0 0
488238D 0 Sendhamarai 61 7 6 0 2 2 0 0 0 7 0 CML 0 0 0 1
491857D 0 Anandhi 59 6 8 housewife 1 4 0 0 0 7 1 pemphigus 0 0 0 1
499070C 0 Abhishek 6 5 2 0 1 3 1 0 0 0 0 0 1 0 0 0
499600C 0 Kavitha's baby 6 5 2 0 1 2 0 0 0 0 0 0 0 0 0 0
501496D 0 Velankanni 5 5 1 0 1 4 0 0 0 0 0 CHILD syndrome 1 0 0 1
504309B 0 Sasikumar 33 6 7 0 1 2 0 0 0 0 0 0 0 0 0 0
504309b 0 Sasikumar 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
504826D 0 Abdul 57 1 6 0 4 4 0 0 0 1 0 0 0 0 0 0
507481D 0 Bijoy Dey 24 6 3 0 4 4 0 0 3 0 0 0 0 0 0 0
507814D 0 Soni Kumari 10 5 2 0 1 3 0 0 0 0 0 0 0 0 0 0
512330D 0 Tsering 29 6 8 monk 4 1 0 0 0 0 0 0 0 0 0 0
512681D 0 Kavin 1 2 1 0 1 3 0 0 0 0 0 Atopic dermatitis 0 0 0 0
514615D 0 Geetha's baby 1 2 1 0 1 3 0 0 0 0 0 0 0 0 0 0
515619D 0 Joydev 42 6 8 business 4 2 0 0 0 0 0 0 0 0 0 0
515792b 0 Pratheesh 33 6 8 doctor 1 2 0 0 0 0 0 0 0 0 0 0
515794D 0 Sneha 23 6 3 0 4 1 0 0 0 0 0 0 0 0 0 0
516021D 1 Joy 42 6 6 0 1 4 0 0 0 5 0 0 1 0 0 0
516439D 1 Chandrahassan 17 6 2 0 4 3 0 0 0 8 0 Nekam's disease 1 0 0 0
516856C 0 Deepalakshmi 5 5 2 0 1 3 0 0 0 0 0 0 0 0 0 0
516995C 0 Sathiya Nirmala's baby4 4 1 0 1 4 0 0 0 0 0 0 1 0 0 0
517849C 0 Arumugasamy 41 6 6 0 1 4 0 0 0 0 0 0 0 0 0 1
519029D 0 Kiran Kumar 26 6 3 0 4 3 0 0 0 0 0 0 0 0 0 0
519481B 0 Karthga Devi 37 6 7 0 1 3 0 0 0 0 0 0 0 0 0 0
520864D 0 Amit 5 5 2 0 4 3 0 0 0 0 0 0 1 0 0 0
522444D 0 Sakuntala 50 6 8 housewife 1 2 0 0 0 1 0 0 0 0 0 0
522653D 0 Haneef 57 6 6 0 4 4 0 0 0 0 0 0 1 0 0 0
523419D 0 Nelson 10 5 2 0 1 4 1 0 0 0 0 0 1 1 0 0
523440D 0 Chandana Das 55 6 8 housewife 1 2 0 0 0 0 0 0 0 0 0 0
523776D 0 Paritosh 57 6 6 0 4 4 0 0 0 0 0 0 0 0 0 0
524351D 0 Ratan 60 6 8 farmer 4 3 0 0 0 8 1 SCC 1 0 0 1
524960D 0 Lambor 31 6 8 service 4 3 0 0 0 0 0 0 1 0 0 0
525099D 0 Kartik 3 4 1 0 4 3 0 0 0 0 0 atopic dermatits 0 0 0 0
525765D 0 Selvaraj 46 6 6 0 1 4 0 0 0 0 0 0 0 0 0 0
527336D 0 Sankha 5 5 2 0 4 2 0 0 0 0 0 0 0 0 0 0
527956D 0 Ganesh Ch Maji 19 6 3 0 4 2 0 0 0 0 0 0 0 0 0 0
529336D 0 Sova Rani 59 6 8 housewife 4 3 0 0 0 0 0 0 0 0 0 0
530127D 0 Ramanathan 59 6 8 clerk 1 3 0 0 0 8 0 psoriasis 0 0 0 0
531370D 0 Ramprasad 31 6 6 0 4 4 0 0 0 0 0 0 0 0 0 0
531859D 0 Saroj 4 4 1 0 4 4 0 0 0 0 0 0 1 0 0 2
533253D 0 Anandan 46 6 6 0 1 4 0 0 0 0 0 0 1 1 0 0
533257D 0 Kenaram Manna 51 6 6 0 1 3 0 0 0 0 0 0 1 0 0 1
534482D 0 Bijaya 48 6 8 housewife 4 3 0 0 0 0 0 0 0 0 0 0
534535C 0 Dhaniksha 4 4 1 0 1 3 0 0 0 0 0 0 0 0 0 0
536767D 0 Dinakaran 27 6 6 0 1 4 0 0 0 0 0 0 0 0 0 0
537005D 0 Sahdeo 13 5 2 0 4 3 0 0 0 0 0 atopic dermatitis 1 0 0 0
537704D 0 Saurav 33 6 7 0 1 1 1 0 0 0 0 0 0 0 0 1
538551B 0 Vignesh 11 5 2 0 1 4 1 0 0 0 0 0 1 0 0 0
541347D 0 Sai Geethika 23 6 3 0 4 1 0 0 0 0 0 0 0 0 0 0
541557D 0 Ram Ekbal 38 6 8 driver 4 3 0 0 0 0 0 0 0 0 0 0
542349D 0 Natarajan 49 6 8 business 1 2 0 0 0 5 0 0 1 0 0 0
542355D 0 Saranya 5 5 1 0 3 3 0 0 0 0 0 0 0 1 0 0
543224D 1 Gopalkrishnan 26 6 3 0 1 1 0 0 0 0 0 arthritis under eval 0 0 0 0
543282D 0 Manjula 39 6 8 housewife 1 1 0 0 0 0 0 0 0 0 0 0
543349D 0 Rita 62 7 8 housewife 4 3 0 0 0 1 1 hypertension 0 0 0 0
543655D 0 SukantA 24 6 3 0 4 3 0 0 0 0 0 0 0 0 0 0
544570D 0 Keithsfield 30 6 7 0 1 3 0 0 0 0 0 0 0 0 0 0
545791D 0 Rupa Shaw 33 6 8 teacher 1 2 0 0 0 0 0 0 0 0 0 0
547059C 0 Sanjay 5 5 2 0 1 4 0 0 0 0 0 0 0 0 0 1
547074D 1 Deepak Kumar 26 6 3 0 4 3 0 0 0 0 0 0 0 0 0 1
547077D 0 Abha Kumari 24 6 3 0 4 2 0 0 0 0 0 0 0 0 0 0
548190D 0 Naveen Kumar 37 6 8 business 4 3 0 0 0 0 0 0 0 0 0 0
550528D 0 satyen 45 6 8 clerk 4 3 0 0 0 0 0 0 0 0 0 0
550792A 0 Thayaramma 74 7 8 housewife 1 1 0 0 0 1 0 0 0 1 0 0
550867b 0 Kalaiselvi 36 6 8 housewife 1 4 0 0 0 0 0 0 0 0 0 0
553369D 0 Sankar 23 6 3 0 1 1 0 0 0 0 0 0 0 0 0 0
555187D 0 Shahinuzzam 34 6 8 business 4 3 0 0 0 0 0 0 0 0 0 0
555662D 0 Dorairaj 81 7 8 retired 1 1 0 0 0 0 0 0 0 0 0 0
555666D 0 Saren 5 5 2 0 4 4 1 0 0 0 0 0 1 0 0 1
557888D 0 Sukla 46 6 8 housewife 4 2 0 0 0 0 0 0 0 0 0 0
560979D 0 Biplab 35 6 8 clerk 4 2 0 0 0 0 0 0 1 0 0 1
560979D 0 Biplab 46 6 8 business 4 3 0 0 0 0 0 0 0 0 0 0
562700d 0 vijaya 33 6 7 housewife 2 2 0 0 0 0 6 0 1 1 2 1
564990D 0 Anju 10 5 2 0 4 2 0 0 0 0 1 osteomyelitis 0 0 0 1
565843D 0 Prasanta 34 6 6 0 4 4 0 0 0 0 0 0 0 0 0 1
569637B 0 Achintya 45 6 8 engineer 4 1 0 0 0 7 1 pemphigus 0 0 0 1
570972D 0 Goverdhanam 29 6 8 business 3 2 0 0 0 0 0 0 1 0 0 0
573529D 0 Jeyachandra 56 6 6 0 4 4 0 0 0 0 0 0 0 0 0 0
574534D 0 Ashish 43 6 8 business 4 3 0 0 0 0 0 0 0 0 0 0
576633D 0 Namrada 30 6 8 housewife 1 2 0 0 0 0 0 0 0 0 0 0
576831D 0 Satan Roy 48 6 8 business 4 3 0 0 0 1 0 0 0 0 0 0
576995D 0 Satyanarayan 37 6 6 0 4 3 0 0 0 0 0 0 0 0 0 0
578693B 0 Kavitha 12 5 2 0 1 4 0 0 0 0 0 0 0 0 0 0
581160D 0 Sheila 46 6 8 housewife 4 2 0 0 0 7 0 0 1 0 0 1
583001A 0 Rajakumar 24 6 7 0 1 1 0 0 0 0 0 0 0 0 0 0
585536D 0 Kasturi 38 6 8 housewife 4 1 0 0 0 7 1 pemphigus 0 0 0 1
585815D 0 Sulendar 46 6 8 business 4 2 0 0 0 0 0 0 1 0 0 1
589015D 0 Riya 2 4 1 0 4 3 0 0 0 0 0 0 0 0 0 0
590540D 0 Ravi Shankar 51 6 6 0 1 4 0 0 0 0 0 0 0 0 0 0
590713D 0 Tapan 22 6 3 0 4 3 0 0 0 0 0 0 0 0 0 0
592097D 0 Shyamalendu 62 7 8 retired 4 2 0 0 0 0 1 0 0 0 0 0
593568D 0 Sahada 14 5 2 0 1 2 0 0 0 8 0 psoriasis 0 0 0 0
594295D 0 Rao Sethumadhavan49 6 8 business 1 1 0 0 0 0 0 0 0 0 0 0
595674D 0 NIvedita 22 6 3 0 4 1 0 0 0 0 0 0 1 1 0 1
601540B 0 Vijayalakshmi 41 6 8 housewife 1 2 0 0 0 1 0 seizure disorder 0 0 0 0
604477b 0 Saravanan 0 6 8 clerk 1 2 0 0 0 0 0 0 0 0 0 0
604618C 0 Anand 30 6 7 0 1 1 0 0 0 0 0 0 0 0 0 0
608805D 0 Usha 65 7 8 housewife 4 1 0 0 0 1 0 0 0 0 0 0
609892d 0 Bhagyalakshmi 65 7 8 housewife 4 2 0 0 0 0 0 0 0 0 0 0
611317D 0 Bidyut 35 6 6 0 4 4 0 0 0 8 0 Hansen's disease 1 0 0 0
611493D 0 Dhanush 6 5 2 0 1 4 0 0 0 8 0 atopi dermatitis 1 0 0 0
612150D 1 Ratan 25 6 3 0 4 4 0 0 0 0 0 0 1 0 0 0
612428D 1 Ranga Reddy 61 7 8 business 4 1 0 0 0 0 0 0 0 0 0 0
612634D 0 Anuka Rai 42 6 8 0 4 3 0 0 0 0 0 0 0 0 0 0
615021C 0 Sanjay 8 5 2 0 1 3 0 0 0 0 0 0 0 0 0 0
632479D 0 Subya Safeen's baby 1 1 1 0 1 4 0 0 0 0 0 0 0 0 0 0
633854D 0 Rajendran 53 6 8 farmer 1 2 0 0 0 0 0 0 0 0 0 1
635762D 0 Preetha 8 5 2 0 3 2 0 0 0 7 1 SLE 0 0 0 0
635895d 1 Pooja 1 2 1 0 2 4 0 0 0 0 1 0 0 0 0 0
639624D 1 Sharoon 15 5 2 0 1 4 0 0 0 0 0 0 1 0 0 0
644191A 0 Vidya 23 6 3 0 1 2 0 0 0 0 0 0 0 0 0 0
644415C 0 Maheshwari's baby 4 4 1 0 1 4 0 0 0 0 0 0 0 0 0 0
644958C 0 Varsha 4 4 2 0 1 3 0 0 0 0 0 0 0 0 0 0
648234C 0 Haradhan 64 7 8 retired teacher 4 2 0 0 0 1 1 DRESS 0 1 0 1
651703d 0 Sonali 4 4 1 0 4 4 0 0 0 7 1 0 0 0 0 1
654095D 0 Narayan 43 6 8 business 4 2 0 0 0 1 0 0 0 0 0 0
654457C 0 Saramma 65 7 8 housewife 1 1 0 0 0 0 0 0 0 0 0 0
655581d 1 Rajiv 20 6 3 0 4 1 1 0 0 0 0 0 0 0 0 0
656338D 0 Subodh Ranjan 65 7 8 retired 4 4 0 0 0 0 0 0 0 0 0 0
657051D 0 Trinayani 45 6 8 healthcare worker 4 2 0 0 0 0 0 0 0 0 0 1
659562D 0 Madhuri 22 6 3 0 4 2 0 0 0 0 0 0 0 0 0 0
660140D 0 Prafulla 47 6 8 0 4 4 0 0 0 0 0 0 1 0 0 1
661891C 0 Shanthi's baby 4 4 1 0 1 3 0 0 0 0 0 0 0 0 0 0
663649D 1 Lubna 7 5 2 0 1 4 0 0 0 0 0 0 1 0 0 1
665258D 0 Jainul 44 6 8 housewife 4 4 0 0 0 0 0 0 1 0 0 1
666385d 0 Rubon 0 0 2 0 4 4 1 0 0 0 0 atopic 0 0 0 0
667224D 0 Atanu 43 6 8 clerk 4 2 0 0 0 0 0 0 1 0 0 0
668693D 0 Sasikala 54 6 8 housewife 1 3 0 0 0 0 0 pemphigus 0 0 0 1
670921D 0 Aryan 2 3 1 0 4 3 0 0 0 0 0 0 0 0 0 0
674167D 0 Yuvaraj 1 2 1 0 1 4 0 0 0 0 0 0 0 0 0 0
674474D 0 Hemamalini 1 1 1 0 1 4 0 0 0 0 0 0 1 0 0 0
674574D 1 Pema Wangmu 43 6 8 teacher 4 2 0 0 0 0 0 0 1 0 0 0
675648d 0 Thangammal 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
675711d 0 Piu bhandari 6 5 2 0 4 4 1 0 0 0 0 0 0 0 0 0
676246d 0 poonambalam 64 7 6 0 1 4 0 0 0 8 1 ca larynx 0 0 0 0
681008D 0 Manoj 30 6 8 business 4 2 0 0 0 0 0 0 0 0 0 0
681254D 0 Asif 24 6 3 0 4 2 0 0 0 0 0 NHL 0 0 0 0
683403D 0 Abdul 1 2 1 0 1 4 0 0 0 0 0 0 0 0 0 0
684978D 0 Murlidhar 25 6 3 0 4 3 0 0 0 0 0 0 0 0 0 0
685178d 0 Janki devi 31 6 8 0 4 3 0 0 0 0 0 0 0 0 0 0
688360D 1 Gita Rani Das 32 6 8 housewife 0 3 0 0 0 0 0 0 0 1 0 1
688763D 0 Surendra 46 6 6 0 1 2 0 0 0 0 0 0 0 0 0 0
688771d 0 Kuppamal 51 6 8 housewife 1 3 0 0 0 0 0 0 0 0 0 0
689990A 0 Anandan 41 6 7 0 1 1 0 0 0 0 0 0 1 1 0 0
690567d 0 Savithri 47 6 8 teacher 3 2 0 0 0 0 0 0 1 0 0 0
691383B 0 Malarvizhi 38 6 8 housewife 1 4 0 0 0 0 0 0 0 0 0 0
695349D 0 Ratna 47 6 8 housewife 4 2 0 0 0 0 0 0 0 0 0 0
696818D 0 Prabhavati 60 7 8 housewife 1 1 0 0 0 0 0 0 0 0 0 1
697249D 0 Wendy 22 6 7 0 4 1 0 0 0 0 0 0 0 0 0 0
698160D 0 Shriya 49 6 8 housewife 1 2 0 0 0 1 0 0 1 1 0 1
698814D 0 Khairul 27 6 6 0 4 3 0 0 0 0 0 0 0 0 0 1
699365D 0 Vevek 20 6 3 0 1 2 0 0 0 0 0 0 1 0 0 0
703075D 0 Hari 1 2 1 0 1 3 0 0 0 0 0 0 0 0 0 0
704035C 0 Arnab 7 5 2 0 4 3 0 0 0 7 1 ALL 0 0 0 1
704173D 0 Elongovan 30 6 8 business 3 2 1 0 0 0 0 0 0 0 0 0
706237B 0 Madhavi 22 6 8 housewife 4 4 0 0 0 0 0 0 0 0 0 0
706661D 0 Mohd Ghose 34 6 8 business 1 4 0 0 0 0 0 0 0 0 0 0
710364D 0 Durai 43 6 6 0 1 2 0 0 0 0 0 0 1 0 0 1
711488D 0 Deendayalu 28 6 6 0 4 4 0 0 0 0 0 0 0 0 0 0
715438D 0 Krishnakumar 45 6 8 weaver 2 3 0 0 0 0 0 0 1 0 0 0
715493D 0 Pradip 42 6 6 0 4 4 0 0 0 0 0 0 0 0 0 0
718055D 1 Bandana 31 6 8 housewife 4 4 0 0 0 0 0 0 1 0 0 1
722401D 0 Noorjahan 56 6 8 housewife 1 4 0 0 0 0 0 0 0 0 0 0
724111D 0 Bhuvaneshwari 41 6 8 housewife 3 3 0 0 0 7 1 Pemphigus 0 1 0 0
727073D 0 Pintu 25 6 3 0 4 4 0 0 0 0 0 0 0 0 0 0
727844D 0 Nitaipada Mandal 66 6 8 teacher 4 3 0 0 0 0 0 0 0 0 0 0
733511C 0 Praveen 49 6 8 clerk 4 2 0 0 0 0 0 0 0 1 0 0
736722A 0 Nissy 49 6 7 0 1 2 0 0 0 0 0 0 1 0 0 0
738973B 0 Lalitha 56 6 8 housewife 3 1 0 0 0 1 0 0 0 0 0 0
742294B 0 Soundaryarajan 86 7 8 retired 1 1 0 0 0 0 0 0 0 0 0 0
750229c 0 Dhanjit 38 6 6 0 4 4 0 0 0 0 0 0 0 0 0 0
762700D 0 Jeevitha 14 5 2 0 1 2 0 0 0 0 0 0 0 0 0 0
766290B 0 Christus 44 6 8 Business 1 2 0 0 0 0 0 0 0 0 0 0
771109 1 Roselyn 56 6 7 0 1 3 0 0 0 0 0 0 0 0 0 0
778841B 0 Ahiya 57 6 8 clerk 4 2 0 0 0 0 0 0 0 0 0 0
799822C 0 Dilip Kumar 56 6 8 Bank employee 4 2 0 0 0 0 0 0 0 1 0 1
808254C 0 rAGHUL 4 4 1 0 1 4 1 0 0 0 0 0 0 0 0 0
809568C 0 Akash 4 4 1 0 1 3 0 0 0 0 0 0 1 0 0 0
816735c 0 Nithiyalaksmi 19 6 3 0 2 1 0 0 0 0 0 0 0 0 0 1
826635C 1 Vedhanayagam 63 7 6 0 2 2 0 0 1 0 0 0 0 0 0 0
839946C 0 Ajith 4 4 1 0 1 4 1 0 0 0 0 0 0 0 0 0
852774A 0 Vasanthi 44 6 7 0 1 3 0 0 0 0 1 0 0 0 0 0
855266A 0 Krishnaveni 80 7 8 housewife 1 1 0 0 0 1 0 0 0 0 0 0
856907c 0 Divya 22 6 3 0 1 1 1 0 0 0 0 0 0 0 0 0
879426C 1 Rohith 4 4 1 0 1 4 1 0 0 0 0 0 1 0 0 0
881197b 0 Kannammal 35 6 8 housewife 1 4 0 0 0 0 0 0 0 0 0 0
890526A 0 Rajesh 20 6 3 0 2 2 1 0 0 0 0 0 0 0 0 0
895460C 0 Krishnan 56 6 6 0 1 3 0 0 0 0 0 0 0 0 0 0
897561B 0 Singhasini devi 62 7 8 housewife 4 3 0 0 0 0 0 0 0 0 0 0
916539 0 Beulah 57 6 8 housewife 1 3 0 0 0 1 0 0 0 1 0 1
922773 0 Luka 24 6 6 0 1 4 0 0 0 0 1 0 0 0 0 1
922773 0 Luka 25 6 7 0 1 4 1 0 0 0 0 0 1 0 0 0
929130C 0 Shanthi's baby 3 4 1 0 1 4 0 0 0 0 0 0 0 0 0 0
936302A 0 Ravikumar 49 6 8 business 1 1 0 0 0 0 0 0 0 0 0 0
937424b 0 Udaya babu 28 6 6 0 1 3 0 0 0 0 0 0 0 0 0 0
954071B 0 Thilagam 66 7 8 housewife 1 1 0 0 0 5 0 0 1 0 0 0
956917C 0 Debnath Mukherjee28 6 8 Bank employee 4 2 0 0 0 0 0 0 0 0 0 0
974452b 0 Arputhamary 49 6 8 housewife 4 2 0 0 0 0 0 0 0 0 0 0
otherantibioticstaken
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historyofrecenttravelhighest ducationstatusinfamilyoccupationstatushighestincomesestatus durationofcomplaintsindayshistoryofpyodermapr viouspyodermatypeotherrecurrentpyodermapain burn itch asymptomaticypeofpyodermamorphologicaltypeoflesionotherpyodermasite size number
0 2 3 1 2 14 1 0 0 -1 0 0 0 1 5 0 1 4 1
0 1 1 1 1 5 3 4 0 -1 0 0 0 1 5 0 4 4 2
0 2 3 3 2 7 1 0 0 0 0 0 0 2 0 0 0 0 0
0 2 3 1 2 2 3 1 0 0 0 -1 0 1 1 0 3 1 4
0 3 4 6 5 2 2 0 0 0 0 0 -1 2 0 0 0 0 0
0 2 2 3 3 7 1 1 0 -1 0 0 0 1 6 0 10 2 2
0 2 3 1 2 3 1 3 0 0 0 0 -1 1 0 0 10 3 2
0 1 1 1 1 14 3 4 0 -1 0 0 0 1 4 0 1 4 2
0 7 6 7 5 3 3 3 0 -1 0 0 0 1 3 0 10 3 3
0 2 3 3 3 3 1 0 0 0 0 0 -1 1 6 0 1 1 2
0 2 2 1 2 300 1 0 0 0 0 0 -1 2 0 0 0 0 0
0 2 3 2 2 3 1 0 0 -1 0 0 0 1 3 0 4 2 2
0 1 1 2 2 5 1 0 0 0 0 0 -1 1 6 ` 10 2 2
0 3 4 4 4 5 1 0 0 0 0 0 0 2 0 0 0 0 0
0 2 1 2 2 6 2 3 0 0 0 0 -1 1 3 0 1 2 2
0 3 2 1 2 3 0 0 0 0 0 0 0 1 7 0 3 3 3
0 2 4 3 3 1 1 0 0 -1 0 0 0 1 6 0 1 1 2
0 2 3 3 2 1 1 0 0 -1 0 0 0 1 7 0 1 2 2
0 3 5 5 4 3 3 4 0 -1 0 0 0 1 3 0 10 4 3
0 3 4 3 3 2 2 3 0 0 0 0 -1 1 6 0 1 3 2
0 3 3 1 2 3 1 0 0 -1 0 0 0 1 8 ULCER 3 3 1
0 4 5 4 4 10 3 4 0 -1 0 0 0 1 3 0 3 3 2
0 4 4 4 4 2 1 0 0 0 0 0 -1 1 5 0 4 3 2
0 2 3 2 3 5 1 0 0 0 0 -1 0 1 1 0 3 2 4
0 1 1 1 1 1 2 3 0 -1 0 0 0 1 6 0 1 3 2
0 2 1 1 1 30 2 0 0 -1 0 0 0 2 0 0 3 4 2
0 5 5 6 4 7 1 4 0 -1 0 0 0 1 0 0 2 3 2
0 2 3 2 2 30 3 0 0 0 0 0 0 2 0 0 3 3 3
0 2 3 2 2 5 3 4 0 -1 0 0 0 1 3 0 4 3 2
0 6 6 6 5 5 3 4 0 -1 0 0 0 1 3 0 3 2 2
0 4 4 4 3 3 3 0 0 0 0 0 0 2 0 0 3 5 0
0 2 3 3 3 5 3 4 0 -1 0 0 0 1 5 0 2 3 2
0 5 6 6 4 7 2 3 0 -1 0 0 0 1 6 0 10 2 3
0 2 2 3 3 5 2 4 0 -1 0 0 0 1 3 0 4 3 2
0 4 6 5 3 14 1 0 0 0 0 -1 0 1 1 0 4 1 4
0 2 2 2 2 7 2 4 0 -1 0 0 0 1 3 0 4 4 1
0 4 3 4 3 5 1 0 0 -1 0 0 0 1 3 0 4 3 1
0 3 3 1 2 5 2 6 0 -1 0 0 0 1 3 0 3 2 2
0 3 5 5 4 5 1 3 0 -1 0 0 0 1 5 0 2 4 1
0 2 3 2 3 5 1 0 0 -1 0 0 0 1 1 0 3 1 4
0 1 1 2 1 7 2 6 0 -1 0 0 0 1 5 0 3 4 1
0 2 3 3 3 5 1 4 0 -1 0 0 0 2 0 0 0 0 0
0 1 1 1 1 7 1 0 0 -1 0 0 0 1 3 0 4 2 1
0 2 2 2 2 2 1 0 0 -1 0 0 0 1 1 0 4 1 4
0 2 3 3 3 3 1 4 0 -1 0 0 0 1 3 0 2 2 2
0 3 4 3 3 5 2 3 0 -1 0 0 0 1 6 0 1 2 2
0 2 3 1 2 3 1 4 0 -1 0 0 0 1 3 0 4 2 2
0 1 1 1 1 7 2 8 secondary infection -1 0 0 0 2 0 0 0 0 0
0 2 3 3 3 4 2 4 0 -1 0 0 0 1 3 0 3 3 2
0 2 2 3 3 2 1 0 0 -1 0 -1 0 1 1 0 3 1 4
0 3 4 4 4 7 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 2 3 2 2 2 1 0 0 -1 0 0 0 1 1 0 3 0 0
0 2 3 1 2 30 1 0 0 -1 0 0 0 1 5 0 0 0 0
0 3 3 3 3 5 3 4 0 -1 0 0 0 1 3 0 2 3 2
0 4 4 5 4 5 1 0 0 0 0 -1 0 1 2 0 3 2 4
0 2 3 1 3 5 1 0 0 0 0 0 -1 1 1 0 1 2 2
0 4 5 6 4 6 1 0 0 -1 0 0 0 1 3 0 0 0 0
0 2 3 3 3 7 1 0 0 0 0 0 -1 1 6 0 2 2 2
0 2 3 2 2 2 1 0 0 -1 0 0 0 1 6 0 1 2 2
0 2 2 2 2 1 1 0 0 0 0 0 -1 1 6 0 10 2 3
0 3 3 2 2 4 1 0 0 0 0 0 -1 1 6 0 1 2 2
0 2 2 2 2 5 3 3 0 0 0 0 -1 1 7 0 1 1 3
0 4 4 4 3 5 1 0 0 -1 0 0 0 2 0 0 3 4 1
0 2 3 1 2 60 1 0 0 -1 0 0 0 1 5 0 0 0 0
0 2 3 2 3 30 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 2 3 5 4 7 1 0 0 -1 0 -1 0 1 1 0 1 3 4
0 2 2 1 1 5 3 4 0 -1 0 0 0 1 3 0 4 4 2
0 5 6 6 4 4 3 4 0 -1 0 0 0 1 3 0 10 3 3
0 4 6 7 5 4 1 0 0 -1 0 0 0 1 5 0 2 4 1
0 2 2 1 1 30 1 0 0 -1 0 0 0 2 0 0 3 0 0
0 6 6 6 5 5 3 4 0 -1 0 0 0 1 3 0 10 3 3
0 6 6 6 5 7 3 8 cellulitis -1 0 0 0 1 3 cellulitis 3 5 1
0 2 3 2 2 1 1 0 0 0 0 0 -1 1 3 0 10 2 2
0 1 1 2 1 28 2 0 hidradenitis 0 0 0 0 2 0 0 0 0 0
0 6 6 6 5 3 3 3 0 -1 0 0 0 1 3 0 1 2 3
0 2 3 2 3 5 1 0 0 -1 0 0 0 1 6 0 10 2 2
0 3 4 4 4 5 1 0 0 -1 0 0 0 1 3 0 4 3 2
0 2 3 3 3 5 2 3 0 0 0 0 -1 1 3 0 2 2 2
0 5 6 5 4 7 1 0 0 -1 0 0 0 1 0 intertrigo 1 4 2
0 1 1 1 1 7 3 4 0 -1 0 0 0 1 3 0 4 3 2
0 2 3 2 3 5 3 0 blister -1 0 0 0 2 0 0 0 0 0
0 2 3 1 2 5 1 0 0 -1 0 0 0 1 3 0 10 3 2
0 2 3 2 3 5 1 0 0 -1 0 0 0 1 0 otitis externa 1 2 1
0 2 3 2 2 5 1 0 0 0 0 -1 0 1 1 0 3 1 4
1 1 1 1 1 3 1 0 0 -1 0 0 0 1 3 0 4 2 2
0 2 3 2 2 7 1 0 0 0 -1 0 0 1 1 0 3 1 1
0 2 3 1 2 5 3 4 0 -1 0 0 0 1 3 0 10 2 3
0 2 1 1 1 7 3 8 acne -1 0 0 0 1 8 acne 1 2 3
0 2 2 2 3 5 1 0 0 0 0 -1 0 1 1 0 3 1 4
0 2 3 2 2 2 0 0 0 0 0 0 0 2 0 0 0 0 0
0 6 6 6 5 7 1 0 0 -1 0 0 0 1 3 0 0 0 0
0 2 3 3 3 5 2 0 0 -1 0 0 0 1 3 0 4 3 1
0 1 1 1 1 2 1 0 0 -1 0 0 0 1 6 0 1 2 2
0 5 5 5 4 7 1 0 0 -1 0 0 0 1 5 0 4 4 1
0 5 4 4 3 5 2 0 0 -1 0 0 0 1 3 0 3 3 2
0 6 5 5 4 5 2 0 0 -1 0 0 0 1 3 0 10 0 0
0 2 4 3 3 5 1 0 0 -1 0 0 0 1 3 0 2 2 2
1 4 5 5 3 5 3 4 0 -1 0 0 0 1 3 0 1 2 4
0 5 5 5 4 7 3 4 0 -1 0 0 0 1 3 0 4 3 3
0 2 3 3 3 2 3 4 0 -1 0 0 0 1 3 0 1 3 2
0 1 1 1 1 3 1 0 0 -1 0 0 0 1 6 0 1 2 0
0 4 4 3 4 7 1 0 0 -1 0 0 0 1 5 0 4 3 2
0 5 5 5 4 7 3 0 0 0 0 0 0 2 0 0 1 0 0
0 1 2 1 1 5 3 4 0 -1 0 0 0 1 3 0 1 3 2
0 2 3 2 3 6 2 3 0 -1 0 0 0 2 0 0 4 0 0
0 6 7 7 5 6 3 8 secndary infection 0 0 0 -1 2 0 0 0 0 0
0 2 3 3 3 5 1 0 0 0 0 -1 0 1 1 0 3 1 1
0 0 0 0 0 5 3 4 0 -1 0 0 0 1 3 0 1 2 1
0 5 6 6 5 7 1 0 0 -1 0 0 0 1 3 0 4 4 2
0 2 3 3 3 6 1 0 0 -1 0 0 0 1 3 0 3 2 2
0 2 3 2 3 2 1 0 0 0 0 0 -1 1 6 0 1 2 2
0 4 7 7 5 5 1 0 0 0 0 0 -1 1 1 0 3 1 3
0 2 3 2 2 10 1 0 0 0 0 -1 0 2 0 0 0 0 0
0 1 2 1 1 2 1 0 0 0 0 0 -1 1 6 0 10 2 3
0 2 3 1 2 7 2 4 0 -1 0 0 0 1 3 0 1 2 2
0 1 1 1 1 3 1 0 0 0 0 0 -1 1 6 0 1 2 2
0 2 3 1 2 7 1 0 0 -1 0 0 0 2 0 0 3 4 2
0 4 4 4 4 7 3 4 0 -1 0 0 0 1 5 0 10 5 2
0 4 5 3 4 7 2 0 0 -1 0 0 0 2 0 0 0 0 0
0 2 2 2 3 7 2 4 0 -1 0 0 0 1 3 0 1 2 2
0 2 2 1 2 6 3 3 0 -1 0 0 0 1 6 0 10 2 4
0 4 4 3 4 7 3 4 0 -1 0 0 0 1 4 0 4 5 1
0 1 1 1 1 5 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 2 2 2 3 7 1 0 0 0 0 0 -1 1 6 0 0 0 0
0 2 3 1 2 2 2 3 0 -1 0 0 0 1 3 0 2 2 2
0 2 2 1 2 5 3 4 0 0 0 0 0 1 3 0 4 3 2
0 5 6 6 4 7 1 0 0 0 0 0 0 2 0 0 1 0 0
0 2 4 1 3 4 3 4 0 -1 0 0 0 1 5 0 4 4 2
0 2 3 2 3 7 1 0 0 -1 0 0 0 1 3 0 4 3 1
0 3 4 4 3 7 2 2 0 -1 0 0 0 1 2 0 4 0 0
0 3 4 3 3 7 3 4 0 -1 0 0 0 1 3 0 10 3 3
0 2 3 2 2 3 2 8 sycosis barbae -1 0 0 0 1 8 sycosis barbae 1 2 2
0 2 3 2 3 7 3 3 0 -1 0 0 0 2 0 0 1 0 0
0 3 5 5 4 5 2 4 0 -1 0 0 0 1 5 0 4 4 2
0 2 3 2 2 6 1 0 0 -1 0 0 0 1 6 0 1 2 2
0 3 3 3 3 5 1 0 0 -1 0 0 0 1 3 0 2 3 2
0 2 2 2 2 7 1 8 infected eczema 0 0 -1 0 2 0 0 0 0 0
0 2 3 2 2 7 3 8 infected psoriasis 0 0 -1 0 2 0 0 10 0 0
0 5 5 6 4 7 3 4 0 -1 0 0 0 1 3 0 1 2 2
0 4 4 4 3 5 3 4 0 -1 0 0 0 1 3 0 10 2 2
0 4 6 6 4 6 3 4 0 -1 0 0 0 1 3 folliculitis legs 10 3 3
0 3 4 5 4 5 3 4 0 -1 0 0 0 1 5 0 4 3 2
0 2 3 3 2 7 1 0 0 -1 0 0 0 1 6 0 1 2 1
0 1 1 2 2 6 2 3 0 -1 0 0 0 1 7 0 3 2 3
0 3 3 3 3 7 1 0 0 -1 0 0 0 1 2 0 3 2 4
0 3 4 5 4 7 1 0 0 -1 0 0 0 1 6 0 10 2 3
0 1 1 1 1 2 1 0 0 -1 0 0 0 1 5 0 1 4 1
0 3 5 5 4 3 2 2 0 -1 0 0 0 1 2 0 10 2 3
0 2 3 1 2 5 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 4 4 3 3 5 2 0 0 -1 0 0 0 2 0 0 3 0 0
0 2 3 1 1 5 3 4 0 -1 0 0 0 1 3 0 10 3 3
0 2 2 2 2 7 3 4 0 -1 0 0 0 1 3 0 10 3 2
0 2 3 2 3 5 1 0 0 -1 0 0 0 1 5 0 2 4 1
0 3 3 3 3 14 1 0 0 0 0 -1 0 2 0 0 0 0 0
0 2 3 1 2 7 1 0 0 -1 0 0 0 1 8 ecthyma 3 4 1
0 2 3 1 3 6 1 0 0 -1 0 0 0 1 3 0 4 3 2
0 1 1 1 1 3 1 0 0 -1 0 0 0 1 2 0 10 2 3
0 1 2 1 1 5 1 0 0 -1 0 0 0 1 5 0 4 4 1
0 3 4 4 3 5 1 0 0 -1 0 0 0 1 7 0 10 3 3
0 2 3 1 2 6 1 0 0 -1 0 0 0 1 0 cellulitis 3 5 1
0 2 3 3 3 2 1 0 0 0 0 -1 0 1 2 0 3 2 4
0 2 3 2 2 5 3 4 0 -1 0 0 0 1 3 0 10 2 3
0 3 3 1 2 5 1 0 0 0 0 0 0 2 0 0 3 0 0
0 2 3 2 2 10 2 4 0 -1 0 0 0 1 0 cellulitis 3 3 2
0 4 3 4 5 5 1 0 0 0 0 0 0 2 0 0 0 0 0
0 3 3 3 3 5 1 0 0 -1 0 0 0 2 0 0 0 0 0
1 2 4 3 2 7 1 0 0 0 0 -1 0 1 0 miliaria pustulosa 4 1 4
0 3 4 3 3 6 1 0 0 -1 0 0 0 1 0 cellulitis 3 5 1
0 2 3 2 2 6 3 3 0 -1 0 0 0 1 3 0 4 3 2
0 2 4 1 2 30 2 0 vesicles -1 0 0 0 2 0 0 0 0 0
0 2 3 3 3 6 2 4 0 -1 0 0 0 1 3 0 2 3 2
0 3 4 3 3 7 1 0 0 -1 0 0 0 1 2 0 4 1 4
0 2 2 2 2 4 3 6 0 -1 0 0 0 1 5 0 3 5 2
0 2 3 2 3 60 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 4 5 5 4 50 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 1 1 1 1 15 3 8 secondary infection -1 -1 0 0 2 0 0 0 0 0
0 2 3 2 3 5 3 4 0 -1 0 0 0 1 3 0 10 3 2
0 3 4 4 3 7 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 3 3 3 2 7 1 0 0 -1 0 0 0 1 2 0 3 3 3
0 2 3 1 2 10 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 2 3 2 2 7 2 2 0 -1 0 0 0 1 3 0 10 2 2
0 3 4 3 3 7 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 1 1 1 1 6 1 0 0 -1 0 0 0 1 6 0 1 2 2
0 3 3 2 3 30 2 8 0 0 0 0 0 2 0 0 0 0 0
0 3 2 3 3 7 1 0 0 -1 0 0 0 1 3 0 3 3 1
0 2 2 2 2 6 2 8 pemphigus erosions -1 0 0 0 2 0 0 0 0 0
0 2 3 1 2 6 3 4 0 -1 0 0 0 1 3 0 10 3 3
0 2 2 2 2 6 1 0 0 0 0 0 -1 1 6 0 1 2 2
0 4 4 4 4 6 1 0 0 -1 0 0 0 1 3 0 4 2 2
0 3 4 3 4 30 1 0 0 0 0 0 0 2 0 0 0 0 0
0 2 2 2 2 7 1 0 0 0 0 -1 0 1 1 0 3 1 4
0 2 4 3 3 60 1 0 0 0 0 0 0 2 0 0 0 0 0
0 2 2 1 2 7 1 0 0 -1 0 0 0 1 5 0 3 4 1
0 1 1 1 1 20 3 8 acne -1 0 0 0 1 2 0 0 0 0
0 3 4 4 4 10 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 2 3 1 2 4 1 0 0 -1 0 0 0 1 3 0 5 3 2
0 1 1 1 1 7 1 0 0 -1 0 0 0 1 3 0 10 3 2
0 2 3 2 2 7 1 0 0 -1 0 0 0 1 5 0 4 4 3
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 4 5 5 4 30 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 3 3 3 3 7 2 4 0 -1 0 -1 0 1 3 0 1 2 2
0 2 3 1 2 7 3 4 0 -1 0 0 0 1 3 0 10 4 3
0 2 3 1 2 7 3 8 secondary infection -1 0 0 0 2 0 0 0 0 0
0 2 3 1 2 3 1 0 0 -1 0 0 0 1 5 0 4 4 1
0 1 1 1 1 1 1 0 0 -1 0 0 0 1 3 0 1 2 2
0 3 5 5 4 3 1 0 0 -1 0 0 0 1 6 0 10 2 3
0 4 5 4 4 7 1 0 0 -1 0 0 0 1 4 0 4 5 1
0 2 3 1 2 7 1 0 0 -1 0 0 0 1 3 0 10 3 3
0 5 5 6 4 6 1 0 0 -1 0 0 0 1 3 0 1 4 2
0 3 3 4 3 7 1 0 0 -1 0 0 0 1 3 0 2 3 1
0 1 2 2 2 4 1 0 0 -1 0 0 0 1 3 0 4 3 1
0 2 4 3 3 8 1 0 0 -1 0 0 0 1 3 0 1 0 0
0 1 1 1 1 7 2 3 0 -1 0 0 0 1 5 0 3 4 1
0 2 2 1 2 20 1 0 0 -1 -1 0 0 0 0 0 0 0 0
0 2 2 1 2 2 0 0 0 0 0 -1 0 2 0 0 0 0 0
0 3 3 1 2 7 1 0 0 -1 0 0 0 1 3 0 2 4 1
0 2 3 1 2 6 1 0 0 0 0 -1 0 2 0 0 0 0 0
0 2 2 2 3 3 3 6 0 -1 0 0 0 1 3 0 2 4 3
0 2 3 2 2 7 2 4 0 0 0 0 0 1 5 0 3 3 1
0 3 4 4 4 7 1 0 0 -1 0 0 0 1 3 0 4 2 2
0 2 3 1 2 7 1 0 0 -1 0 0 0 1 2 0 7 2 4
0 3 3 3 3 10 2 4 0 -1 0 0 0 1 3 0 3 4 2
0 2 2 2 2 7 1 0 0 -1 0 0 0 1 7 0 3 3 2
0 4 5 5 4 6 3 4 0 -1 0 0 0 1 3 0 10 3 3
0 4 4 3 3 7 2 4 0 -1 0 0 0 1 5 0 3 1 1
0 4 4 3 3 4 1 0 0 -1 0 0 0 1 5 0 2 4 1
0 3 3 3 3 7 1 0 0 -1 0 0 0 1 3 0 2 2 2
0 3 4 3 3 5 1 0 0 -1 -1 0 0 2 0 0 4 0 0
0 3 2 2 2 5 1 0 0 -1 0 0 0 1 7 0 10 2 2
0 2 2 2 2 3 1 0 0 -1 0 0 0 1 3 0 1 4 2
0 3 3 3 3 7 1 0 0 -1 0 0 0 1 6 0 10 2 2
0 3 3 2 3 7 3 4 0 -1 0 0 0 1 5 0 10 5 4
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 2 3 1 2 5 1 0 0 0 0 -1 0 1 6 0 1 2 2
0 2 3 2 2 7 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 3 4 4 4 7 1 0 0 -1 0 0 0 1 2 0 3 3 2
0 3 4 4 2 7 1 0 0 -1 0 0 0 1 3 0 5 4 3
0 6 6 6 5 3 1 0 0 -1 0 0 0 1 3 0 10 4 3
0 3 3 2 3 15 1 0 0 -1 0 0 0 1 0 acute paronychia 3 3 1
0 4 4 3 3 3 1 0 0 -1 0 0 0 1 5 0 1 4 2
0 3 4 4 3 8 2 2 0 -1 0 0 0 1 3 0 3 2 2
0 3 3 2 3 7 2 1 0 -1 0 -1 0 1 1 0 3 1 4
0 5 5 4 3 7 1 0 0 -1 0 0 0 1 5 0 2 4 1
0 2 2 1 2 7 2 2 0 -1 0 0 0 1 2 0 5 3 2
0 2 1 1 1 10 1 0 0 -1 0 0 0 1 5 0 3 4 1
0 3 3 3 3 8 1 0 0 -1 0 0 0 1 3 0 3 4 2
0 5 5 5 4 8 1 0 0 -1 0 0 0 1 3 0 3 2 2
0 3 4 1 3 10 2 2 0 -1 0 0 0 1 3 0 2 2 2
0 1 1 1 1 2 1 0 0 0 0 -1 0 1 1 0 3 2 4
0 3 3 3 3 8 2 1 0 -1 0 0 0 1 1 0 3 1 3
0 4 4 4 3 5 3 0 0 -1 0 0 0 2 0 0 0 0 0
0 4 4 2 3 7 3 1 0 -1 0 0 0 1 1 0 3 3 2
0 2 3 3 2 7 1 0 0 -1 0 0 0 1 6 0 1 2 2
0 3 3 2 2 2 1 0 0 0 0 -1 0 1 1 0 3 1 3
0 3 3 4 3 7 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 4 6 6 4 7 1 0 0 -1 0 0 0 1 3 0 3 3 1
0 5 6 4 4 7 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 4 4 4 3 3 3 4 0 -1 0 0 0 1 3 0 10 3 3
0 3 3 3 3 7 1 0 0 -1 0 0 0 1 1 0 3 2 4
0 4 4 3 3 5 2 4 0 -1 0 0 0 1 1 0 10 1 4
0 4 5 3 3 7 1 0 0 -1 0 0 0 1 8 Ulceronodular lesion 3 5 1
0 3 4 3 3 7 3 4 0 -1 0 0 0 1 5 0 10 4 3
0 2 3 2 2 8 1 0 0 -1 0 0 0 1 3 0 10 2 3
0 2 3 2 2 30 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 3 3 3 2 5 1 0 0 -1 0 0 0 1 3 0 3 2 2
0 2 2 2 2 7 1 0 0 -1 0 0 0 1 2 0 1 1 2
0 3 2 2 2 7 3 2 0 -1 0 0 0 1 2 0 10 2 2
0 2 2 2 2 3 1 0 0 -1 0 0 0 1 2 0 4 1 3
0 3 3 3 3 6 2 1 0 0 0 0 0 2 0 0 0 0 0
0 2 2 2 1 5 3 0 0 0 0 -1 0 2 0 0 0 0 0
0 3 4 4 3 5 1 4 0 -1 0 0 0 1 3 0 7 4 2
0 4 3 3 3 5 0 0 0 0 0 0 0 2 0 0 0 0 0
0 3 2 2 2 7 2 4 0 -1 0 0 0 1 3 0 4 2 3
0 1 1 1 1 1 1 1 0 0 0 -1 0 1 1 0 3 1 4
0 3 3 2 2 7 1 0 0 -1 0 0 0 1 3 0 4 3 2
0 2 2 1 2 60 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 3 2 3 3 8 1 0 0 0 0 0 0 1 7 0 10 2 2
0 2 3 2 3 5 1 0 0 0 0 0 -1 1 6 0 1 3 2
0 1 1 1 1 21 2 0 0 0 0 0 0 2 0 0 0 0 0
0 4 5 4 3 7 2 4 0 -1 0 0 0 1 5 0 3 4 1
0 2 2 1 1 4 1 0 0 0 0 0 -1 1 6 0 1 2 2
0 1 1 1 1 7 1 0 0 -1 0 0 0 1 1 0 3 2 4
0 2 3 2 2 7 1 0 0 -1 0 0 0 1 3 0 4 3 0
1 1 1 1 1 5 1 0 0 -1 0 0 0 1 3 0 4 3 2
0 2 2 2 2 3 1 0 0 -1 0 0 0 1 3 0 10 3 2
0 6 6 6 4 10 1 0 0 -1 0 0 0 1 8 ecthyma 10 4 2
0 2 3 1 2 30 1 0 0 -1 0 0 0 1 2 0 7 3 3
0 4 4 3 3 30 1 0 0 -1 0 0 0 2 0 0 0 0 0
0 3 2 3 3 6 1 0 0 -1 0 0 0 1 3 0 4 2 3
0 3 3 2 2 3 3 4 0 -1 0 0 0 1 3 0 2 2 2
0 3 5 5 3 5 1 1 0 0 0 0 -1 2 0 0 0 0 0
0 3 4 4 4 7 1 0 0 0 0 -1 0 1 1 0 1 1 3
0 2 2 1 1 7 1 0 0 -1 0 0 0 1 6 0 1 1 2
0 2 2 1 2 3 1 0 0 -1 0 0 0 1 3 0 4 4 2
0 2 3 2 2 5 3 1 0 -1 0 0 0 1 1 0 9 2 4
0 2 2 2 2 7 1 0 0 -1 0 0 0 1 3 0 3 4 2
0 2 2 1 1 5 1 0 0 -1 0 0 0 1 6 0 1 2 1
0 2 2 1 1 5 1 0 0 -1 0 0 0 1 6 0 1 2 1
surroundingerythemadeeperinvolvementn croticchangeslymphangitislympphadenpathyfever secondarypyodermaoth secondarypyodermasadiditi nalinfouniquekey recstatus lympphadenpathy1deeperinvolvement1n croticchanges1lymphangitis1fever1 secondarypyoderma1oth secondarypyodermas1adiditi nalinfo1
0 0 0 0 0 0 0 0 0 25 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 47 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 48 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 33 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 49 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 50 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 51 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 52 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 54 1 1 1 0 0 1 0 0 0
0 0 0 0 0 0 0 0 0 55 1 1 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 3 1 0 0 0 0 0 0 0 post melanoma surgery ulcer
1 0 0 0 0 0 0 0 0 56 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 57 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 35 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 58 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 23 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 59 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 60 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 61 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 62 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 63 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 64 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 65 1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 66 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 67 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 3 0 0 68 1 1 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 69 1 0 0 1 0 0 0 0 0
0 0 0 0 0 0 3 0 0 70 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 71 1 1 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 72 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 73 1 0 0 0 0 0 0 stasis dermatitis 0
1 0 0 0 0 0 0 0 0 74 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 75 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 76 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 22 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 77 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 78 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 79 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 80 1 0 0 0 1 0 0 0 0
0 0 0 0 0 0 0 0 0 81 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 82 1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 83 1 0 0 0 0 0 0 0 asteatotic eczema
0 0 0 0 0 0 0 0 0 84 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 42 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 85 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 86 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 87 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 4 0 0 88 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 43 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 89 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 90 1 0 0 0 0 0 0 0 stasis dermatitis
0 0 0 0 0 0 0 0 0 91 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 92 1 0 0 0 0 1 0 0 0
1 0 0 0 0 0 0 0 0 93 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 94 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 95 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 96 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 97 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 98 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 99 1 1 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 21 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 19 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 100 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 101 1 0 1 0 0 0 0 0 panniculitis
0 0 0 0 0 0 2 0 0 102 1 0 0 0 0 0 0 0 stasis dermatits
1 0 0 0 0 0 0 0 0 103 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 104 1 0 0 0 1 1 0 0 0
1 0 0 0 0 0 0 0 0 105 1 0 1 0 0 1 0 0 0
1 0 0 0 0 0 0 0 0 106 1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 107 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 108 1 0 0 1 0 0 0 0 0
1 0 0 0 0 0 0 0 0 109 1 0 1 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 110 1 1 0 0 0 0 0 0 MOther healthcare worker
0 0 0 0 0 0 0 0 0 111 1 0 0 0 0 0 0 hidradenitis 0
1 0 0 0 0 0 0 0 0 112 1 1 0 0 0 1 0 0 0
1 0 0 0 0 0 0 0 0 113 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 114 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 115 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 116 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 117 1 0 0 1 0 0 0 0 0
0 0 0 0 0 0 5 0 0 118 1 0 0 0 0 0 0 infected erosionsEpidermolysis bullosa
1 0 0 0 0 0 0 0 0 119 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 120 1 1 0 0 1 0 0 0 0
0 0 0 0 0 0 0 0 0 121 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 122 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 123 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 124 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 125 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 126 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 5 0 0 24 1 0 0 0 0 0 0 infected sebaceous cyst0
1 0 0 0 0 0 0 0 0 127 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 128 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 129 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 130 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 131 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 132 1 0 0 1 1 0 0 0 0
1 0 0 0 0 0 0 0 0 133 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 4 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 134 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 36 1 1 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 135 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 136 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 4 0 0 137 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 138 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 139 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 140 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 141 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 13 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 142 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 143 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 144 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 145 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 0 0 146 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 147 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 148 1 1 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 29 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 149 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 150 1 0 1 1 1 0 0 0 0
0 0 0 0 0 0 2 0 0 151 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 152 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 153 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 154 1 0 0 0 1 0 0 0 0
0 0 0 0 0 0 2 0 0 34 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 155 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 37 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 40 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 156 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 41 1 0 1 1 0 0 0 0 0
1 0 0 0 0 0 0 0 0 157 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 158 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 159 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 160 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 0 0 161 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 162 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 163 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 164 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 165 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 5 0 0 166 1 0 0 0 0 0 0 psoriasis 0
1 0 0 0 0 0 0 0 0 167 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 168 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 169 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 170 1 1 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 171 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 172 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 173 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 174 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 175 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 176 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 177 1 0 0 0 0 0 0 0 infected biopsy site
0 0 0 0 0 0 2 0 0 178 1 0 0 0 1 0 0 stasis dermatitis 0
1 0 0 0 0 0 0 0 0 179 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 180 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 181 1 0 0 1 1 0 0 0 0
0 0 0 0 0 0 2 0 0 182 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 183 1 0 0 1 0 0 0 0 0
1 0 0 0 0 0 0 0 0 184 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 185 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 186 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 187 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 188 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 189 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 190 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 191 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 192 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 12 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 193 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 194 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 195 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 196 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 5 0 0 197 1 0 0 0 0 0 0 subcorneal pustular dermatosis0
1 0 0 0 0 0 0 0 0 199 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 198 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 200 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 3 0 0 201 1 0 1 1 0 0 0 0 0
0 0 0 0 0 0 4 0 0 202 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 203 1 0 0 1 0 0 0 0 0
0 0 0 0 0 0 4 0 0 204 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 205 1 1 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 206 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 207 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 3 0 0 208 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 209 1 1 0 0 0 0 0 0 0
0 0 0 0 0 0 4 0 0 210 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 211 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 4 0 0 212 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 213 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 214 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 215 1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 216 1 0 0 0 0 0 0 0 Hansen's ulcer
0 0 0 0 0 0 0 0 0 217 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 5 0 0 218 1 0 0 0 0 0 0 psoriasis with secondary infection0
1 0 0 0 0 0 0 0 0 219 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 220 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 5 0 0 221 1 0 0 0 0 0 0 TEN 0
1 0 0 0 0 0 0 0 0 7 1 0 0 1 0 0 0 0 0
1 0 0 0 0 0 0 0 0 222 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 223 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 18 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 224 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 225 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 226 1 0 0 1 1 0 0 0 0
0 0 0 0 0 0 2 0 0 227 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 228 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 229 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 230 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 231 1 0 1 0 0 1 0 0 0
1 0 0 0 0 0 0 0 0 232 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 30 1 1 0 1 0 0 0 0 0
1 0 0 0 0 0 0 0 0 233 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 234 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 235 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 236 1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 5 0 0 237 1 0 0 0 0 0 0 DRESS with secondary infection0
0 0 0 0 0 0 2 0 0 17 1 0 0 0 0 0 0 0 scabies
1 0 0 0 0 0 0 0 0 238 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 239 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 31 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 240 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 241 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 242 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 243 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 244 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 245 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 246 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 9 1 0 0 0 0 0 0 0 atopic
1 0 0 0 0 0 0 0 0 247 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 4 0 0 248 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 249 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 250 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 251 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 252 1 0 1 1 0 0 0 0 0
0 0 0 0 0 0 0 0 0 8 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 26 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 5 1 0 0 1 0 0 0 0 decubitus ulcer
1 0 0 0 0 0 0 0 0 253 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 254 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 255 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 256 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 6 1 1 1 0 0 1 0 0 0
1 0 0 0 0 0 0 0 0 257 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 258 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 14 1 0 0 1 0 0 0 0 0
1 0 0 0 0 0 0 0 0 259 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 10 1 0 0 1 1 0 0 0 0
1 0 0 0 0 0 0 0 0 260 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 261 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 262 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 263 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 264 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 0 0 265 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 266 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 267 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 268 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 2 0 0 269 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 270 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 271 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 272 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 273 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 274 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 275 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 276 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 277 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 4 0 0 278 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 279 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 280 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 281 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 282 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 5 0 0 283 1 0 0 0 0 0 0 TEN 0
0 0 0 0 0 0 2 0 0 284 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 28 1 0 0 1 0 0 0 0 0
0 0 0 0 0 0 2 0 0 285 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 286 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 44 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 287 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 288 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 39 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 38 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 4 0 0 27 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 289 1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 290 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 291 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 292 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 11 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 293 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 20 1 0 0 1 0 0 0 0 0
1 0 0 0 0 0 0 0 0 294 1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 3 0 0 295 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 296 1 0 0 1 0 0 0 0 0
1 0 0 0 0 0 0 0 0 45 1 0 1 0 0 1 0 0 0
0 0 0 0 0 0 5 0 0 16 1 0 0 0 0 0 0 psoriasis 0
1 0 0 0 0 0 0 0 0 46 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 297 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 298 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 2 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 299 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 300 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 301 1 0 0 0 0 0 0 0 0
staphaureuscons strep pseudomonasenterococcusklebsiella morganella proteus otherbacteriamssa betalactam macrolide quinolones tetracyclinescotrimoxazolelinezolid others topicalfucidicacistopicalclindamycin
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0
1 0 1 0 0 0 0 0 E.coli 1 1 0 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 citrobacte 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 1 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 NFGNB 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0
0 0 0 1 1 0 0 1 0 0 1 1 0 0 0 1 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 1 0 0 0 0 e.coli 0 0 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 NFGNB 1 0 0 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 No growth 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 1 0 0 1 1 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0
0 0 0 0 0 0 0 0 contaminan 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 1 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0
0 0 0 0 0 0 0 0 contaminan 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 no growth 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 1 E.coli 0 0 0 0 0 0 0 0 1 0
1 0 0 0 0 1 0 0 E.coli 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 1 0 0 0 0
1 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 1 0 1 0 0 1 0 0 1 1 0 0 0 0 1 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 Enterobact 1 1 1 1 1 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 NFGNB 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 1 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 NFGNB 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 no growth 0 0 1 0 1 0 0 0 0 0
0 0 0 0 0 0 0 0 citrobacte 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 No growth 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 enterobact 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 hemophilus 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 citrobacte 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 E.coli 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0
0 0 0 0 1 0 0 0 citrobacte 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0
0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 no growth 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 1 0 0 enterobact 0 0 0 0 0 0 0 0 0 0
0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 citrobacte 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0
1 1 0 0 1 0 0 0 0 0 1 0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0
1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 1 E.coli 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 E.coli 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 enterobact 0 1 1 0 0 1 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 NFGNB 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 NFGNB 0 0 0 0 0 0 0 0 0 0
0 0 0 1 0 0 0 0 E.coli 0 1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 NFGNB 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 1 0
1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 No growth 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 0 0 0 0 1 1 0 0 1 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 E.coli 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 No growth 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 No growth 0 1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 0 0 No growth 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 1 0 0 1 0 0 E.coli 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 NFGNB 0 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 M.tubercul 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0
1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 No growth 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 No growth 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 1 0 0 Enterobact 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 No growth 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 No growth 0 0 0 0 0 0 0 0 0 0
topicalneosporint picalmupirocinmi rono gender multiple anti
0 0 0 0 0 0
0 0 0 1 1 0
0 0 0 2 3 0
0 0 0 2 1 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 2 2 0
1 0 0 1 1 3
0 0 0 1 2 1
0 0 0 2 1 0
0 0 0 0 1 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 2 0
0 0 0 2 1 4
0 0 0 0 0 0
0 0 0 1 1 0
0 0 0 1 2 0
0 0 0 1 2 2
0 0 0 2 2 0
0 0 0 1 1 0
0 0 0 2 2 0
0 0 0 2 1 0
0 0 0 2 1 0
0 0 0 2 1 2
0 0 0 1 3 3
0 0 0 1 1 0
0 0 0 1 1 2
0 0 0 1 1 1
0 0 0 1 1 0
1 0 0 2 1 2
0 0 0 1 1 0
0 0 0 1 1 1
0 0 0 1 1 0
0 0 0 0 0 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 2 2 0
0 0 0 1 2 0
0 0 0 1 0 1
0 0 0 2 1 2
0 0 0 1 1 0
0 0 0 1 0 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 3
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 1 1 3
0 0 0 2 0 1
0 0 0 1 1 2
0 0 0 2 1 2
0 0 0 1 2 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 0 0 0
0 0 0 0 0 2
0 0 0 1 0 0
0 0 0 2 0 1
0 0 0 1 2 1
0 0 0 1 2 1
0 0 0 2 1 3
0 0 0 1 2 1
0 0 0 2 1 0
0 0 0 2 4 2
0 0 0 1 1 2
0 0 0 1 1 5
0 0 0 1 1 0
0 0 0 2 1 1
1 0 0 1 1 3
0 0 0 1 1 1
0 0 0 1 1 0
0 0 0 2 1 2
0 0 0 1 1 0
1 0 0 1 1 4
1 1 0 1 2 3
0 0 0 1 1 0
0 0 0 2 1 2
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 0
1 0 0 1 1 3
0 0 0 2 0 3
0 0 0 2 0 0
0 0 0 0 0 0
0 0 0 1 0 0
0 0 0 1 1 0
0 0 0 2 1 1
0 0 0 1 1 0
0 0 0 2 1 3
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 0 0 0
0 0 0 1 1 2
0 0 0 1 1 0
0 0 0 1 1 1
0 0 0 1 1 2
0 0 0 2 1 2
0 0 0 1 1 0
0 0 0 2 1 0
0 1 0 2 2 2
0 0 0 1 1 0
0 0 0 0 0 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 2 2 0
0 0 0 1 1 0
0 0 0 1 0 0
0 0 0 2 1 0
0 0 0 1 1 1
0 0 0 1 1 0
0 0 0 2 1 0
1 0 0 2 3 1
0 0 0 1 1 3
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 2 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 1 1 1
0 0 0 2 1 0
0 0 0 1 2 0
0 0 0 1 1 1
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 2 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 2 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 1
0 0 0 1 1 2
0 0 0 2 1 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 2
0 0 0 1 2 1
0 0 0 2 1 1
1 0 0 1 0 1
0 0 0 1 1 2
0 0 0 2 1 1
0 0 0 1 1 0
0 0 0 2 3 0
0 0 0 2 2 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 2 1 0
0 0 0 1 1 2
1 0 0 1 1 2
0 0 0 2 1 0
0 0 0 1 2 1
0 0 0 1 2 0
0 0 0 2 1 1
0 0 0 0 0 0
0 0 0 1 3 0
0 0 0 1 1 0
0 0 0 1 1 0
0 1 0 1 1 2
0 0 0 2 1 0
0 0 0 1 1 2
0 0 0 1 1 0
0 0 0 0 1 2
0 0 0 2 3 2
0 0 0 1 1 1
1 0 0 1 2 2
0 0 0 1 2 0
0 0 0 1 1 1
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 1 1
0 0 0 1 4 0
0 0 0 2 1 0
0 0 0 2 1 2
0 0 0 1 1 0
0 0 0 2 1 0
1 0 0 1 2 2
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 2 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 2 0 3
0 0 0 2 1 0
0 0 0 0 0 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 0 0 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 1
0 0 0 1 1 1
0 0 0 2 2 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 2
0 0 0 2 1 0
0 0 0 2 0 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 2 0
0 0 0 2 1 0
0 0 0 1 1 2
0 0 0 0 0 3
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 2 1 0
0 0 0 1 1 2
0 0 0 1 2 0
0 0 0 2 1 3
1 1 0 2 1 3
0 0 0 0 0 0
0 0 0 1 1 0
0 0 0 2 0 1
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 2 1 0
0 0 0 0 0 0
0 0 0 0 1 0
0 0 0 0 0 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 0 0 0
1 0 0 2 1 3
0 0 0 1 1 0
0 0 0 0 0 0
0 0 0 1 1 3
0 0 0 0 0 0
0 0 0 2 1 0
0 0 0 2 1 0
1 1 0 2 0 2
0 0 0 2 1 0
0 0 0 2 1 2
0 0 0 1 1 1
0 0 0 1 2 0
0 0 0 1 2 0
0 0 0 1 0 2
0 0 0 1 0 0
0 0 0 2 1 0
0 0 0 1 3 0
0 0 0 1 2 2
0 0 0 1 1 0
1 0 0 1 2 2
0 0 0 1 0 0
1 0 0 2 1 3
0 0 0 2 2 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 1 1 1
0 0 0 2 2 0
0 0 0 2 0 0
0 0 0 1 1 0
0 0 0 1 0 0
0 0 0 2 0 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 1 0
1 1 0 1 1 3
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 0 1 2
0 0 0 1 1 0
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 2 2 0
0 0 0 0 0 0
0 0 0 1 1 0
0 0 0 0 0 0
0 0 0 1 1 0
0 0 0 1 2 0
0 0 0 2 1 0
1 0 0 2 1 3
0 0 0 0 0 1
0 0 0 1 1 0
0 0 0 2 1 0
0 0 0 1 1 0
0 0 0 0 1 0
0 0 0 2 1 0
0 0 0 1 0 0
0 0 0 1 0 0
  
 
Pic 1: Gel run for PVL following PCR showing 5 positive strains 
 
 
 
Pic 2: Gel run following PCR showing 11 PVL positive strains 
 
(Key PC: positive control, NC: negative control) 
